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Abstract 
 
Glioblastoma (GBM) is the most common and aggressive primary central nervous 
system malignancy. It is a grade IV tumour, the incidence of which peaks during the 75-
84 age group, however, it can occur at any age, including childhood. Incidence is also 
slightly higher in men compared to in women, possibly due to the significantly less active 
retinoblastoma protein in males compared to in women. Despite current treatment 
options including surgical resection, radiation and chemotherapy, GBM has the poorest 
overall survival rate of gliomas, with only 0.05-4% of patients surviving 5 years after 
diagnosis. A combination of increasing drug resistance and the inability of many drugs 
to cross the blood-brain barrier, requires novel therapies for GBM to be established. 
Combination treatments have been proven to have a beneficial effect on increasing the 
sensitivity of GBM cells to therapy. This study investigated whether PARP1 could be a 
therapeutic target for GBM, measuring the effects of PARP1 inhibition by olaparib, alone 
and in combination with temozolomide and cisplatin on cell viability, proliferation, cell 
cycle arrest, apoptosis and autophagy in U87-MG grade IV glioblastoma and SVG p12 
foetal glia cell lines cultured under normoxic (21% O2) and hypoxic (1% O2) conditions. 
The results show that olaparib monotherapy had little effect on cell viability in U87-MG 
cells. It decreased proliferation following 48- and 72-hours of treatment under normoxia. 
The combination treatment of olaparib and cisplatin was observed to induce apoptosis 
in a greater proportion of U87-MG cells in comparison to olaparib monotherapy under 
both normoxia and hypoxia following 48- and 72-hours. Whereas, both combinations with 
temozolomide and cisplatin induced greater autophagy when compared to olaparib 
following 24-hours of treatment. In the comet assay, olaparib was also observed to 
induce DNA damage in the U87-MG cells 24-hours after treatment. In conclusion the 
results of this study show that olaparib induces cytotoxic effects on glioma cells and has 
the potential to become an alternative treatment for GBM, whether alone or in 
combination with the current chemotherapeutics.  
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Chapter 1: 
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1.1 Cancer 
 
Cancer is the second leading cause of death worldwide and was responsible for an 
estimated 9.6 million deaths in 2018 (Bray, et al., 2018), and it is predicted that in the 
UK, 1 in 2 people born after 1960 will be diagnosed with some form of cancer during their 
lifetime. There are over 100 types of cancers worldwide, but the most common are 
breast, lung, prostate and bowel cancer (NHS, 2016), however the probability of 
developing cancer depends on many factors, such as age, genetics, and exposure to 
risk factors (Cancer Research UK, 2018). The highest proportion of cases diagnosed at 
an early stage, for all cancers combined, is by the route of screening (Cancer Research 
UK, 2018). The initial treatment option for most cancer types is surgery, as solid tumours 
can usually be surgically removed, but also other commonly used treatments are 
chemotherapy and radiotherapy (NHS, 2016). Cancer can also metastasise by 
spreading to another area of the body from its site of origin and this is when a primary 
cancer becomes secondary.  
 
One cancer with a high mortality rate is a grade IV glioblastoma (GBM), a type of 
glioma, which affects the central nervous system (CNS), especially the brain. The 
incidence of GBM usually peaks during the 75-84 age group, but it can also affect 
younger people (Davis, 2016). This study employed U87-MG and SVG p12 glial cell lines 
to study the anti-cancer effects of three drugs, namely olaparib, temozolomide and 
cisplatin. 
 
 
1.2 Glioma 
 
Less than 2% of all primary cancers are comprised of brain tumours,  which when 
they originate in the neuroglial cells, are referred to as gliomas (Longworth, 2005). 
Gliomas are the most common intracranial tumours and approximately 30% of all brain 
and central nervous system (CNS) tumours are made up of gliomas, and also, they 
represent approximately 80% of all malignant brain tumours in adults (Goodenberger & 
Jenkins, 2012). Despite their prevalence, the aetiology of gliomas remains largely 
unknown, but when diagnosed they cause significant mortality and morbidity (Ostrom, et 
al., 2014). People of all ages can be affected but are most often diagnosed in adults aged 
45-60 years and young children <6 years, and they are more commonly seen in men 
compared to women. 
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Gliomas have been classified following genomic studies which identified individual 
molecular subtypes within “glioma” that were seen to correlate with biological aetiology, 
prognosis and response to therapy. By determining these subtypes, it suggests that 
molecular genetic tests are and will be useful, further than classical histology, for the 
clinical classification of gliomas (Goodenberger & Jenkins, 2012). 
 
 
1.2.1 Classification & Grading 
 
Depending on their cell of origin, gliomas have been divided into four main types: 
astrocytic, oligodendroglial, a mix of these two cell types (oligoastrocytic), and 
ependymal tumours (Ostrom, et al., 2014). Further classifications have been 
summarised in Table 1.1.  
 
Gliomas are categorised according to the World Health Organisation (WHO) grading 
system, where grades I-IV are based on the malignant behaviour of the tumour. The 
most frequently occurring histological types of gliomas in adults are astrocytoma (grade 
I-IV), oligodendroglioma (grade II-III), and oligoastrocytoma (grade II-III) (Table 1.1), with 
ependymomas (grade I-III) being extremely rare (Ostrom, et al., 2014). The grades of 
the tumours are also classified according to their likely rate of growth; from grade I being 
the slowest growing, to grade IV being fast growing (Longworth, 2005). Grades I-III are 
classed as low-grade gliomas, while grade IV gliomas are referred to as high-grade due 
to their rapid progression (Louis, et al., 2018). 
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Table 1.1: The classification of glioma tumours according to the 2016 WHO classification 
system: identifying the grade, incidence, and the approximate age of onset (Louis, et al., 
2016). 
 
 
 
1.3 Glioblastoma 
 
Glioblastoma (GBM) is the most common and aggressive primary CNS malignancy, 
comprising approximately 16% of all primary brain and CNS neoplasms (Thakkar, et al., 
2014) and 60-75% of astrocytic tumours (Young, et al., 2015). A term previously 
synonymous with glioblastoma was glioblastoma multiforme, however “multiforme” is no 
longer associated with the WHO classification (Young, et al., 2015). GBM is now divided 
into three types, namely wild-type, mutant-type, and not otherwise specified. This will be 
discussed further in the next paragraph. GBM is a grade IV tumour, whose cell type of 
origin is yet to be elucidated (Jawhari, et al., 2016). The age of incidence of GBM peaks 
during the 75-84 age group, however it can occur at any age, including childhood. 
Incidence is also slightly higher in men compared to in women (Davis, 2016), with males 
being diagnosed twice as often compared to females. A possible reason for this was 
Glioma type Name Grade Incidence  
(% of all brain 
tumours) 
Age 
Astrocytic 
tumours 
Pilocytic astrocytoma Grade I 5-6% First 2 
decades 
Subependymal giant 
cell astrocytoma 
Grade II <1% 2-20 
Pilomyxoid 
astrocytoma 
1.9% 10-18 months 
Pleomorphic 
xanthoastrocytoma 
<1% 10-30 
Diffuse astrocytoma 10-15% 30-40 
Anaplastic 
astrocytoma 
Grade III 10-15% 45-50 
Glioblastoma Grade IV 12-15% 45-84 
Oligodendroglial 
tumours 
Oligodendroglioma Grade II 2.5% 40-45 
Anaplastic  
oligodendroglioma 
Grade III 1.2% 45-50 
Oligoastrocytic 
tumours 
Oligoastrocytoma Grade II 1.8% 35-45 
Anaplastic 
oligoastrocytoma 
Grade III 1% 40-45 
Ependymal 
tumours 
Subependymoma Grade I 0.7% 50-60 
 Myxopapillary 
ependymoma 
0.3% 20-35 
 Ependymoma Grade II 4.7% <16, 30-40 
 Anaplastic 
ependymoma 
Grade III 1% <16 
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found when researchers established that the retinoblastoma protein, which is known to 
reduce the risk of cancer, is significantly less active in male brain cells than in female 
brain cells (Purdy, 2014; Sun, et al., 2014). Glioblastoma has the poorest overall survival 
rate of gliomas, with only 0.05-4% of patients surviving 5 years after diagnosis. Age is 
significantly associated with survival in all gliomas, but the effect is most obvious in GBM 
patients (Ostrom, et al., 2014). It constitutes the second leading cause of death by cancer 
in children after leukaemia and the third leading in adults (Jawhari, et al., 2016). GBM 
can be classified as either primary or secondary, depending on its site of origin and 
clinical presentation. The majority of glioblastomas (80-85%) are primary tumours, that 
can arise without a known precursor. These primary tumours develop rapidly, as most 
patients show either signs or symptoms less than six months before diagnosis. 
Secondary GBM is where a low-grade tumour from elsewhere in the body that has 
metastasised and transformed into GBM overtime. These patients will usually show signs 
and/or symptoms for longer than six months  (Goodenberger & Jenkins, 2012). Those 
diagnosed with a primary GBM tend to be older aged and have a poorer prognosis, 
compared to those with secondary GBM (Davis, 2016). 
 
According to the 2016 CNS WHO classification system, glioblastomas are divided 
into glioblastoma isocitrate dehydrogenase (IDH) wild-type, glioblastoma IDH mutant-
type and glioblastoma not otherwise specified (NOS). IDH wild-type accounts for about 
90-95% of cases and is most frequently associated with the clinically defined primary or 
de-novo glioblastoma and is predominantly observed in patients aged 55+. IDH mutant-
type accounts for only 10% of cases mainly arising in younger patients. IDH wild and 
mutant-type are classified as grade IV tumours by the 2016 WHO classification. The 
glioblastoma NOS designation is a diagnosis for those tumours for which a full IDH 
evaluation cannot be completed. However, a full IDH evaluation differs for glioblastomas 
present in older patients compared to those in younger adults (Louis, et al., 2016). 
 
Isocitrate dehydrogenase is a catalytic isozyme encoded by five genes that express 
the three key IDH human types, that are involved in the citric acid cycle and it also plays 
a role in the protection of cells against oxidative damage. Mutations within IDH1 and 
IDH2 occur in 70-80% of low-grade gliomas and secondary glioblastomas, but only in a 
small proportion of primary glioblastomas (5-10%) (Ostrom, et al., 2014). These 
mutations alter the function of the enzymes, resulting in the production of 2-
hydroxyglutarate, a potential oncometabolite, and lack of nicotinamide adenine 
dinucleotide phosphate (NADPH) production (Cohen, et al., 2013). These mutations are 
associated with glioblastoma IDH mutant-type and is believed to arise spontaneously 
(Brown, et al., 2010). IDH1 and IDH2 mutated GBM has a better prognosis compared to 
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GBM IDH-wild type. Patients with GBM IDH-mutant type have a mean overall survival 
time of 27.1 months, which is more than twice as long as than those with GBM IDH-wild 
type (11.3 months) (Ohgaki & Kleihues, 2013). 
 
The GBM tumour environment contains areas of low tumour oxygenation, also 
known as hypoxia (Jawhari, et al., 2016), a condition frequent in solid tumours. Due to 
GBM being an extremely hypoxic tumour, deep and remote areas of the growth suffer 
from a low oxygen partial-pressure, which could drop to 1% or less. Although, 
expectations are that these conditions should slow tumour growth, instead the cancer 
cells develop processes overtime enabling them to not only survive hypoxia, but to also 
become more aggressive. In the midst of these adaptive responses, autophagy, a 
catabolic mechanism, aids in the survival of tumour cells. This survival pathway allows 
cell components to be degraded resulting in the production of energy (adenosine 
triphosphate (ATP)) and metabolic precursors to be further recycled by the cellular 
anabolism (Jawhari, et al., 2016). Hypoxia constitutes a major issue for GBM patients, 
since it induces tumour cell invasion into healthy brain tissue in order to evade the 
adverse environment. As well as being a major obstacle for therapy, tumour invasion is 
also the leading cause of death in GBM patients (Monteiro, et al., 2017). Due to this 
reason, a large amount of research has been focused on characterising the molecular 
and cellular pathways which regulate GBM cell invasiveness. Since the hypoxic condition 
is a major inducer of the invasive phenotype, understanding how hypoxia triggers GBM 
cells to invade, or how this can be prevented, is essential for the development of novel 
and more effective therapies against glioblastoma (Monteiro, et al., 2017). 
 
 
1.4 Diagnosis of GBM 
 
Symptoms of glioblastoma can vary widely, as they are dependent on the size and 
the location of the tumour. The most commonly observed symptoms include headaches, 
nausea, dizziness, seizures, physical weakness, visual loss, memory problems, 
personality changes or stroke-like symptoms (Young, et al., 2015). Symptoms can 
worsen as the tumour progresses. During the first stage of diagnosis when a patient 
presents any neurological symptoms, a physical exam will be performed. This will include 
neurologic functions tests, such as muscle strength, alertness, eye and mouth movement 
and coordination. If, following this, a tumour is suspected, imaging tests including either 
magnetic resonance imaging (MRI) or computerised tomography (CT) will be done to 
identify any abnormalities in the patient’s brain (Ramakrishna, 2017). Determination of a 
patient’s tumour subtype requires an invasive biopsy or surgical resection in order to 
perform genomic analysis (Davis, 2016). 
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1.5 Treatment of GBM 
 
Treatment options for GBM patients are limited and have remained largely 
unchanged over the past 40 years. This includes surgical resection, radiation and 
chemotherapy (Young, et al., 2015). Complete and extensive surgical resection of the 
tumour is most likely impossible, because GBM tumours are frequently invasive and are 
often located in essential areas of the brain; areas which control speech, motor function, 
and the senses. Therefore, the amount of tumour which is safe to be removed will be 
surgically resected. However, due to the high degree of invasiveness, radical resection 
of the primary mass of tumour is non-curative, and invading GBM cells will remain within 
the brain region, resulting in later GBM progression or recurrence (Davis, 2016). The 
importance of aggressive surgical resection when possible has been demonstrated by 
multiple studies, by showing trends of a better outcome in those patients who have a 
greater extent of resection (Kuhnt, et al., 2011). A surgical resection of 98% or more of 
the tumour volume has a median survival of 13 months, compared to 8.8 months for 
resections of less than 98% (Lacroix, et al., 2001). Thus, a significant correlation is seen 
between the extent of resection and longer progression-free survival and overall survival. 
 
More recently enhancements in surgical and pre-operative brain mapping 
techniques have also made it possible to achieve more extensive surgical resection, 
while preserving function and quality of life (Davis, 2016). The use of imaging techniques, 
such as functional MRI and diffusion tensor imaging (DTI) in pre-operative planning, as 
well as ultrasound, CT scans, and MRI with direct stimulation during surgery has made 
multimodal neuro-navigation and the integration of patient-specific anatomic and function 
data possible. Regardless of these technologies, differentiating between normal brain 
cells and tumour cells continues to be a great challenge, and the use of 5-aminolevulinic 
acid (5-ALA) dye for fluorescent guidance is more effective than neuro-navigation-guided 
surgery alone (Zhao, et al., 2013). However, there are limitations to these novel 
techniques, such as cost, the need for specialised equipment, operators and surgery 
suites. Therefore, further studies are required to elucidate the clinical benefits, prior to 
being established as the standard care for patients with GBM (Davis, 2016). 
 
Opportunities for new therapies for recurrent and newly diagnosed GBM have come 
to light by significant advances in the knowledge and understanding of the molecular 
pathology of GBM and the accompanying cell signalling pathways. Due to survival being 
short-term, new advances in treatment are greatly required to prolong a GBM patient’s 
survival (Davis, 2016). 
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1.5.1 Radiation & Chemotherapy 
 
Following surgical resection, the patient will commonly wait as long as four weeks 
for the craniotomy wound to heal, before commencing therapy. Post-operative radiation 
therapy (RT) alone was the standard treatment until 2005, until a pivotal phase III trial 
improved the standard of care for GBM. It was confirmed that external beam RT 
combined with temozolomide (TMZ) chemotherapy was more effective than RT alone 
(Stupp, et al., 2005; Davis, 2016). 
 
RT occupies an integral role in GBM treatment. Analysis of the relationship between 
survival and the dose of radiation administered, revealed a dose-effect relationship. The 
usual dose of 60 gray units (Gy), given in 30 fractions of 2 Gy, provided superior survival 
in comparison to lower doses (Mann, et al., 2017); and a dose escalation beyond this 
identified increased toxicity, without additional survival benefits (Davis, 2016). However, 
from recent findings patients who received TMZ chemotherapy along with RT had a 
median survival of 14.6 months, compared to 12.1 months with RT alone. The cohort of 
patients who received TMZ plus RT also had a higher proportion of long-term survivors 
compared to those who received RT alone (27% vs. 11% at two years; 10% vs. 2% at 
five years, respectively) (Stupp, et al., 2009). RT and alkylating chemotherapy exert their 
therapeutic effects by initiating DNA damage, cytotoxicity and triggering apoptosis 
(Davis, 2016).  
 
 
1.5.2 Temozolomide 
 
Temozolomide is an imidazotetrazine derivative of the alkylating agent dacarbazine 
and a prodrug of the anti-cancer drug, Temodar (Moody & Wheelhouse, 2014). TMZ was 
approved in 2005 by the US Food and Drug Administration (FDA) for the treatment of 
newly diagnosed adult GBM. TMZ is administered orally, due to its lipophilic nature 
allowing it to penetrate through the blood-brain-barrier (BBB). As a DNA alkylating agent, 
it induces cell cycle arrest during the G2/M phase, eventually resulting in apoptosis. The 
cytotoxicity caused by TMZ is mediated in genomic DNA by its addition of methyl groups 
at N7 and O6 sites on guanines, and the N3 site on adenines. Alkylation of the O6 site on 
guanine results in the insertion of a thymine base instead of a cytosine opposite to the 
methyl-guanine, during subsequent DNA replication, which can ultimately cause cell 
death (Fig.1.1) (Lee, 2016).  
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However, 50% of patients given TMZ do not respond to it, and this is primarily due 
to the over-expression of the O6-methylguanine methyltransferase (MGMT) enzyme 
(Lee, 2016). The MGMT gene codes for the MGMT enzyme, which is involved in DNA 
repair, thus patients with methylated (non-activated) MGMT present with compromised 
DNA repair. Activation of the MGMT enzyme can cause interference with the effects of 
treatment, therefore, patients who express methylated MGMT benefit further when 
undergoing chemotherapy with TMZ and RT (Stupp, et al., 2009; Davis, 2016). 
 
 
Figure 1.1: Flow diagram showing the mechanism of action of temozolomide for the 
treatment of cancer, leading to the induction of cytotoxicity (Annovazzi, et al., 2017). 
 
 
1.5.3 Cisplatin 
 
Otherwise known as cisplatinum, or cis-diamminedichloroplatinum (II), cisplatin is a 
well-known chemotherapeutic drug. It has been used as a treatment for numerous 
human cancers, such as bladder, testicular, ovarian, head and neck, and lung cancers.  
Its mechanism of action (MOA) has been associated with its ability to cross-link with the 
N7 reactive centre of purine bases in DNA. This causes interference with DNA repair 
mechanisms, initiating DNA damage in cells and blocking cell division, to consequently 
induce apoptotic cell death (Dasari & Tchounwou, 2014). Even though cisplatin is one of 
the most commonly used and effective anti-cancer drugs, high doses are frequently 
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required for it to penetrate the BBB; which usually causes intolerable adverse effects in 
patients. Furthermore, 90-95% of cisplatin becomes irreversibly bound to plasma 
proteins, resulting in only 5-10% of the drug which is fraction free to exert anti-tumour 
effects (Coluccia, et al., 2018). Regarding brain tumours, cisplatin has been used as a 
treatment for recurrent childhood brain tumours (Dasari & Tchounwou, 2014). As TMZ is 
a prodrug that can display inconsistent activities in vitro, in this project cisplatin was used 
as a consistent control.  
 
 
1.6 PARP1 
 
PARP (poly ADP-ribose polymerase) enzymes comprise of a large family of 18 
proteins (Dziadkowiec, et al., 2016). PARP1 is an abundant nuclear protein that is 
involved in many cellular processes from DNA repair to cell death. Recognition of DNA 
breaks by PARP1 is one of the initial steps that occur following DNA damage. When 
DNA strand breaks occur, particularly due to ionising radiation or DNA alkylating agents, 
including temozolomide, PARP1 binds to the break sites through its N-terminal zinc 
finger motifs which are located in the DNA-binding domain. This causes activation of its 
catalytic C-terminal domain which initiates hydrolysis of NAD+, by transferring an ADP-
ribose moiety, to synthesise poly-(ADP-ribose) (PAR) polymers, which are covalently 
bound to different acceptor proteins or to PARP1 itself. The auto-poly(ADP-ribosyl)ation 
results in chromatin decondensation at the break site, allowing access for repair 
enzymes. A key mechanism of PARP1-dependent decondensation is that the removal 
of the H1 linker histone from transcription initiation sites is facilitated by an activated 
PARP1. Removal of H1 causes chromatin decondensation, allowing repair enzymes to 
cleave to the damaged DNA sites, forming a repair complex (Malyuchenko, et al., 2015). 
Eventually, PARP1 undergoes a molecular modification that ultimately results in its 
reduced affinity for DNA. The dissociation of PARP1 from DNA is required for DNA repair 
completion (Dziadkowiec, et al., 2016). The active involvement of PARP1 in DNA repair 
occurs only upon minimal genotoxic damage. Stronger damage would trigger apoptosis, 
though more extensive DNA damage would cause overactivation of PARP1, resulting in 
cell necrosis (Fig.1.2) (Malyuchenko, et al., 2015). 
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Figure 1.2: Diagrams A and B depicting the role of PARP1 in the DNA repair pathway 
(Chen, 2011). 
 
 
 
Abundant data have found PARP1 to be involved in carcinogenesis. Inhibition of 
PARP1 by olaparib leads to disruption of many cellular pathways. Disturbances in the 
DNA repair process and inhibition of the transcription of various genes involved in DNA 
replication and cell cycle regulation are caused by the loss of PARP1. Under-expression 
of the enzyme leads to genome shuffling and chromosomal abnormalities, and it may 
contribute to overall genome instability. In contrast, increased expression of PARP1 has 
been observed in many tumours, including GBM, which is considered as a prognostic 
factor associated with poor survival (Malyuchenko, et al., 2015). 
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Figure 1.3: Diagram showing the mechanism of action of PARP1 and PARP inhibitors 
on DNA following chemotherapy (Powell, 2014).  
 
 
Even though PARP1 is over-expressed in the nuclei of GBM cells, it is barely 
detectable in normal brain tissue (Fulton, et al., 2018). Therefore, PARP may represent 
a tumour-specific treatment target. As well as assisting rapidly dividing cancer cells with 
DNA repair, PARP1 counteracts apoptotic cell death. Interference of PARP function by 
inhibition renders cancer cells to be more prone to the cytotoxic effects of DNA-damaging 
treatments (Karpel-Massler, et al., 2014). 
 
 
1.7  Olaparib 
 
Also known by the trade name Lynparza, olaparib is used as a targeted therapy, and 
in 2014, was approved by the FDA as treatment for advanced ovarian cancer in patients 
with inherited BRCA mutations who have had three or more types of chemotherapy. The 
FDA granted regular approval for olaparib, in 2017, as maintenance therapy for patients 
with recurring epithelial ovarian, fallopian tube, or primary peritoneal cancer, who were 
either partially or completely responsive to platinum-based chemotherapy (Sharples, 
2017). This was further approved by the European Medicines Agency (EMA) in 2018 
(AstraZeneca, 2018). Olaparib was granted regular approval by the FDA in January 2018 
also for the treatment of deleterious or suspected deleterious germline-BRCA-mutated, 
HER2-negative metastatic breast cancer in patients who had received chemotherapy in 
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the neoadjuvant, adjuvant or metastatic setting. This is the first FDA-approved treatment 
for these patients (FDA, 2018).  
 
In recent studies, olaparib has been investigated for the treatment of glioblastoma. 
The OPARATIC trial managed by Professor Anthony Chalmers (University of Glasgow) 
obtained results of olaparib successfully penetrating both the core and outer-area of 
recurrent GBM, despite failing to penetrate an intact BBB (Jenkins, 2017). It was able to 
leak through because the barrier is disrupted in GBM. By elucidating that olaparib was 
able to reach the tumours, it can be utilised to enhance current treatments and make 
them more effective. Olaparib combined with low dose TMZ was also discovered as 
being safe and endurable, which allowed promising 6-month progression-free survival 
rates. These results suggest olaparib could be a potential treatment strategy for GBM 
tumours. This study has already caused two further clinical trials to commence, 
PARADIGM and PARADIGM-2, which investigate olaparib in combination with TMZ and 
radiotherapy in patients with newly diagnosed GBM (Jenkins, 2017).  
 
Olaparib is a member of a class of drugs, known as PARP enzyme inhibitors. The 
focus in this project will be on PARP1 inhibition by olaparib. PARP inhibitors (PARPi), 
such as olaparib, sensitise cancer cells to DNA damaging agents and functions through 
synthetic lethality in cells containing defects in homologous recombination (HR) DNA 
repair (Lim & Tan, 2017). Single-strand breaks (SSBs) activate PARP1 in order to repair 
the damage. Olaparib inhibits PARP by trapping it at the unrepaired SSB sites on DNA, 
which induces the production of DNA double-strand breaks (DSBs), that require HR for 
successful repair (Brown, et al., 2016). The accumulation of these breaks induces cell 
apoptosis, which subsequently allows the effects of the therapeutics to be more effective 
and cause enhanced apoptosis (Fig.1.3) (Chalmers, 2017). Preclinical studies have 
indicated that only 10-100 nM of olaparib is required to achieve >90% PARP inhibition 
(Chalmers, et al., 2016). 
 
 
1.8 Drug Resistance 
 
Effectiveness of cancer therapy becomes limited due to drug resistance – a serious 
issue that results when diseases become tolerant to pharmaceutical treatments. There 
are two broad categories into which resistance to chemotherapeutics can be divided: 
intrinsic or acquired. Intrinsic drug resistance refers to the pre-existence of resistance-
mediating factors in the bulk of the tumour cells even before receiving chemotherapy, 
causing the therapy to be ineffective. However, acquired resistance can develop during 
treatment. These tumours can be initially susceptible, but resistance can be due to 
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mutations arising during treatment. Various other adaptive responses, including 
increased expression of the therapeutic target and activation of alternative compensatory 
signalling pathways can also result in acquired drug resistance (Holohan, et al., 2013).  
 
Treatment of drug resistant GBM is a complex goal due to the heterogeneous nature 
of GBM tumours and the inherent issues of treating any cancer of the CNS because of 
the limited repair mechanisms and anatomic complications. The molecular pathways by 
which GBM presents resistance to apoptosis, are only partially understood. However, by 
understanding the molecular relationship between GBM cells and their environment is 
vital since these abnormalities could determine tumour formation and progression. This 
process can be reversible via therapeutic targeting, resulting in restoration of 
susceptibility to apoptosis. Thus, by recognising the cellular and molecular mechanisms 
that are involved in drug resistance is an essential target for the treatment of GBM (Haar, 
et al., 2012). 
 
GBM can become resistant to current post-operative therapies, contributing to the 
poor survival prognosis of GBM patients. Evidence is available that increased PARP1 
expression and treatment resistance of tumours are correlated (Malyuchenko, et al., 
2015). Upregulation of PARP1 enhances the anti-apoptotic feature of GBM, leading to 
resistance to DNA-damaging therapeutic agents. Therefore, restoring apoptotic 
sensitivity is of vital importance to render GBM cells sensitive to treatment (Karpel-
Massler, et al., 2014). PARP1 can also become resistant to PARPi, though it is largely 
unknown how this resistance develops. (Murnyák, et al., 2017). PARPi have been seen 
to cause synthetic lethality in cells with defects in HR DNA repair as a result of molecular 
abnormalities including BRCA mutations. Resistance of PARPi can therefore also be 
caused when BRCA1/2 function is restored through mutations which result in repair of 
the open reading frames of the gene (Lim & Tan, 2017). 
 
 
1.9 Combination Therapies 
 
Administration of combination drug regimens is one way to make treatment resistant 
GBM responsive to drug therapy, as such treatments have the potential to overcome 
intrinsic and acquired resistance to therapy. The majority of all GBMs develop treatment 
resistance after administration of TMZ, radiation, or the combination of TMZ and radiation 
(Karpel-Massler, et al., 2014). The discovery of small molecule PARPi was driven by 
their potential to enhance the cytotoxic effects of commonly used cancer therapies for 
GBM.  
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Temozolomide mediates its cytotoxic effects by binding alkyl groups to nitrogen 
atoms in guanine bases in DNA. The synergistic interaction of TMZ and PARPi has 
appeared, at least partly, to be dependent upon the ability of PARPi to trap PARP on 
DNA. Olaparib has found to have a great ability to trap PARP1 on DNA, which enhances 
the cytotoxic effects of TMZ to a great extent. The TMZ-PARPi synergistic effect is 
suggested to be associated to the role of PARP1 in the repair of abasic sites in DNA 
(short “gaps” in the double helix which lack a base). PARP1 especially attaches to DNA 
lesions with 5’-deoxyribose phosphate ends, as opposed to 5’-phosphate ends; possibly 
elucidating why TMZ induces a greater level of PARP DNA binding, and also in the 
presence of TMZ why more DNA-PARP complexes occur, which in turn enhances 
cytotoxic effects of PARPi caused by efficient PARP trapping. In preclinical models, the 
TMZ-PARPi combination has been seen to be effective in targeting models of GBM, also 
including models which are usually TMZ-resistant. High doses of PARPi treatment 
combined with a low dose of TMZ has improved TMZ efficacy; dose-limiting toxicity is 
often a factor of TMZ treatment. Therefore, a combined treatment approach that utilises 
a low dose of TMZ with an increased dose of a PARPi may reduce toxicity while still 
maintaining efficacy (Dréan, et al., 2016).  
 
Early studies demonstrated that PARP inhibition causes radio-sensitisation in 
mammalian cells (Malyuchenko, et al., 2015; Ben-Hur, et al., 1985). Later it was 
discovered that various PARPi, such as olaparib, enhanced the radio-sensitisation 
efficacy in some cell lines. Other studies observed that PARPi selectively induces radio-
sensitisation of actively replicating cells during the S-phase of the cell cycle. Therefore, 
this observation suggests a mechanism that PARP inhibition increases the sensitivity to 
ionising radiation as inhibition prevents SSBs repair, converting them into DSBs during 
the movement of the replication fork in the S-phase, hence resulting in cell death 
(Malyuchenko, et al., 2015). These radio-sensitising effects of PARP inhibition have been 
observed in multiple glioma cell lines but are only present in actively dividing cells. Since 
normal brain tissue is comprised almost entirely of non-dividing cells, combining 
radiotherapy with PARPi is expected to improve its therapeutic effects (Fulton, et al., 
2018). 
 
 
1.10 Model Cell Lines 
 
U87-MG cells are epithelial cells, derived from brain tissue and are a grade IV 
glioblastoma cell line that were developed almost 50 years ago (Pontén & Macintyre, 
1968). U87-MG cells are possibly the most commonly used cell line for research on 
human glioma as there were 408 publications on PubMed, which used these cells, in 
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2018. This cell line is currently available from the American Type Culture Collection 
(ATCC), but the original cell line was generated by Uppsala. These two versions of the 
cell line are not identical, possibly due to the occurrence of cross-contamination, but they 
both are glioblastoma cell lines (Allen, et al., 2016).  
 
SVG p12 cells are fibroblast cells, derived from brain tissue and are a human foetal 
glial cell line that was generated in 1985 (Major, et al., 1985). SVG p12 cells have been 
provided by the ATCC since 1987 and have been used in various research studies where 
cells of neural origin are required  (Henriksen, et al., 2014).  
 
 
1.11 Gaps in Knowledge 
 
Over the past decade, a vast amount of research has been performed on 
glioblastoma, with numerous published papers focusing on prognosis, treatment 
response and treatment targets; though, not many studies have caused changes in 
patient outcome. A novel approach for therapy is greatly required to address the 
overwhelmingly poor survival and treatment results for patients diagnosed with GBM 
(Ozdemir-Kaynak, et al., 2018).  
 
Olaparib’s effects in GBM are currently being studied, and due to the illness causing 
the BBB in patients to become leaky, this allows olaparib to enter the CNS (Chalmers, 
2017). However, limited knowledge is available about whether the drug has a potential 
to be a treatment for GBM. Therefore, more testing is required to ensure it can be used 
as a treatment alone or in combination with the current standard chemotherapeutics. 
Also, due to the intra-tumoural environment of GBM being hypoxic (Jawhari, et al., 2016), 
the MOA of olaparib in low oxygen conditions also requires research in order to establish 
whether olaparib would be effective on hypoxic cancer cells.  
 
Inhibiting PARP1 may be a potential and promising therapeutic target, though no 
previous study has determined the expression characteristics and prognostic role 
associated with the molecular heterogeneity in astrocytomas, including GBM, of PARP1 
(Murnyák, et al., 2017). Therefore, thorough research is required, so its role as a DNA 
repair protein in GBM can be elucidated.  
 
These experiments are necessary because currently there is no curative treatment 
for GBM and the survival rate is considerably low (Lee, 2016). Therefore, investigation 
into whether olaparib can improve a patient’s chances of survival is required. However, 
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if survival is an unrealistic goal, it could be observed whether olaparib can be used to 
improve a patient’s life conditions. This may be possible if olaparib has fewer side effects 
or even less harmful effects, compared to those caused by current chemotherapeutic 
agents. 
 
 
1.12 Hypothesis  
 
The overall survival rate of glioblastoma is very poor, and as the treatment options 
are limited, a novel therapy is highly required. Therefore, in this study it was decided to 
investigate the effects of olaparib, a PARP1 inhibitor, on U87-MG cells. Olaparib was 
investigated alone and in combination with either TMZ and cisplatin in various assays. 
 
It is hypothesised that olaparib will cause enhanced cytotoxicity in glioblastoma cells 
when used as a treatment alone and in combination with standard chemotherapeutic 
agents. 
 
Main Aim: To investigate olaparib as a novel treatment for glioblastoma when 
administered either alone or in combination with other standard chemotherapeutic 
agents, such as temozolomide and cisplatin. 
 
Objectives:  
• To establish whether olaparib effects the growth, viability, proliferation, cell cycle 
arrest, apoptosis, autophagy and colony formation of glioma cells.  
• To confirm DNA damage by olaparib by performing the comet assay. 
• To establish the effects of olaparib in both normoxic and hypoxic conditions. 
• To determine the cytotoxic effects of olaparib alone and in combination with either 
temozolomide and cisplatin on glioma cells. 
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Chapter 2: 
 
 
Materials and Methods  
 28 
2.1 Materials 
 
Consumables were of the highest grade commercially available and purchased from 
the following suppliers: SVG p12 and U87-MG cell lines (The European Collection of 
Authenticated Cell Cultures (ECACC)), olaparib, temozolomide, cisplatin (Cambridge 
Bioscience), Eagles Minimum Essential Media (EMEM), Trypan blue (Lonza), 
PrestoBlue® viability reagent (ThermoFisher Scientific), propidium iodide (PI) dye 
(Sigma), carboxyfluorescein diacetate succinimidyl ester (CFDA-SE) (ThermoFisher 
Scientific), apoptosis assay kit (ThermoFisher Scientific), autophagy kit (Enzo), Hoescht 
33342 (Life Technologies), crystal violet (Sigma). All other consumables were of the 
highest available and purchased from Sigma.  
 
 
2.2 Tissue Culture 
 
SVG p12 and U87-MG cell lines were maintained in EMEM supplemented with 10% 
foetal bovine serum (FBS), 1mM sodium pyruvate, 2mM L-glutamine and 1% non-
essential amino acids in a 37C humidified atmosphere with 5% CO2. When 
approximately 80% confluency was reached, the cell monolayers were washed with 1x 
phosphate-buffered saline (PBS) solution, which was replaced with trypsin and returned 
to the incubator to allow the cells to detach from the surface of the flask for approximately 
5 minutes. After detachment, EMEM was added to neutralise the trypsin. The cells were 
gently re-suspended to ensure a single cell suspension was obtained before passaging 
or seeding into plates for experimental analysis.  
 
 
2.3 PrestoBlue® Cell Viability Assay 
 
Both concentration and time-dependent effects on cell viability were measured over 
3-days of drug treatment. SVG p12 and U87-MG cells were seeded at 1000 cells/well in 
96-well plates prior to drug treatment with olaparib, temozolomide and cisplatin at various 
concentrations (0.001 mM, 0.003 mM, 0.01 mM, 0.03 mM, 0.1 mM, 0.3 mM) to measure 
cell viability at 24, 48 and 72-hour time-points. Following treatment, PrestoBlue reagent 
was added to the wells and after an incubation period of 1-hour, the fluorescence was 
measured at Ex 535 nm/Em 612 nm using the Tecan GENios Pro plate reader. This 
assay was performed in normoxic (21% O2) and in hypoxic (1% O2) conditions to 
compare the viability of the drug treated cells in normal and reduced oxygen levels. From 
the concentration-time curves, the IC50 and IC25 values were determined for each of the 
drug treatments using GraphPad Prism software. 
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2.4 CFDA-SE Cell Proliferation Assay & PI staining for Cell Cycle Assay 
 
SVG p12 and U87-MG cells were seeded at 50,000 cells/well in 6-well plates for the 
day 0 controls and 10,000 cells/well in 12-well plates for measuring the effects of drug 
treatment on cell proliferation and cell cycle over a period of 7-days. This assay was 
performed in both normoxic and hypoxic conditions. Following seeding, the cells were 
incubated for 24-hours prior to the addition of carboxyfluorescein diacetate succinimidyl 
ester (CFDA-SE) dye (5 M in PBS). After 10 minutes, the CFDA-SE solution was 
replaced with fresh medium and incubated for 2-hours prior to drug treatment and the 
drug treatments were added to the appropriately labelled wells using the previously 
calculated IC25 values of olaparib (100 M), temozolomide (100 M) and cisplatin (10 
M). Day 0 controls and then 24, 48, 72, 144 and 168-hours post-treatment, cells were 
harvested by trypsinisation, followed by fixation in 70% ice cold methanol until the 
samples were analysed. Before analysis, cells were counterstained with propidium iodide 
(PI; 5g/ml in 1X PBS with 250 g/mlRNase) and incubated for 1-hour at 37°C in the 
dark. Changes in cell proliferation and cell cycle were measured at Ex 492 nm/Em 517 
nm by flow cytometry where 5000 events were analysed using the Guava easyCyte 
12HT benchtop flow cytometer (Merck Millipore, UK). 
 
 
2.5 Annexin V & PI Staining for Cell Apoptosis Assay 
 
Effects of olaparib, TMZ and cisplatin on apoptosis, in normoxia and in hypoxia, were 
investigated on SVG p12 and U87-MG cells, over 3-days. The cell lines were seeded at 
25,000 cells/well in a 24-well plate and incubated for 24-hours, prior to drug treatment. 
Previously calculated IC50 values of each of the drugs were used: a concentration of 300 
M for all three drug treatments. At 24, 48 and 72-hours post-treatment, the cells were 
harvested by trypsinisation. Prior to analysis, the PI (1 µg/ml) and Annexin V stains were 
prepared and added to each labelled sample according to the manufacturer’s instructions 
(ThermoFisher Scientific), before transferring into a 96-well plate. After incubation for 30 
minutes at room temperature, the samples were analysed by flow cytometry where 5000 
events were analysed using the Guava easyCyte 12HT benchtop flow cytometer, at Ex 
488 nm/Em 530 nm and 575 nm (Merck Millipore, UK). 
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2.6 Autophagy Assay 
 
SVG p12 and U87-MG cell lines were seeded at 50,000 cells/well in 24-well plates 
to investigate the effects on autophagy at 24-hours. This assay was performed in both 
normoxia and hypoxia in order to compare the differences in normal oxygen conditions 
and in reduced oxygen conditions. Each appropriate well was drug treated with the 
previous calculated IC50 values: a concentration of 300 M for all three drug treatments, 
including the combination treatment wells 24-hours before analysis. The positive 
controls, rapamycin (10 M) and chloroquine (200 M), were added to the appropriate 
wells 16-18 hours prior to harvesting. The following day, the 1X assay buffer and the 
diluted CYTO-ID green stain solution (0.5 l/ml) were prepared, as per the 
manufacturer’s instructions (Enzo) and protected from light. The cells were harvested by 
trypsinisation and centrifuged for 5 minutes, at 4C, at 100 xg. After removing the 
supernatant, the cells were resuspended in EMEM and diluted CYTO-ID stain solution; 
1 X assay buffer was added to the unstained samples instead of the stain. The samples 
were incubated for 30 minutes at 37C, in the dark, before centrifugation again. Finally, 
the cells were resuspended in PBS, transferred into a 96-well plate and analysed by flow 
cytometry where 5000 events were analysed using the Guava easyCyte 12HT 
benchtop flow cytometer, at Ex 483 nm/Em 506 nm (Merck Millipore, UK). The normoxia 
and hypoxia graphs were created by calculating the percentage of each of the non-
treated controls for each cell line. Whereas, for the normoxia and hypoxia comparison 
graphs, percentages were calculated from the normoxia non-treated control for each cell 
line. 
 
 
2.7 Comet Assay 
 
SVG p12 and U87-MG cells were seeded at 50,000 cells/well in 6-well plates to 
measure DNA damage at the individual eukaryotic cell level. This assay was performed 
in normoxic conditions only. A final concentration of 300 M, obtained from the previously 
calculated IC50 values, was used of olaparib, TMZ and cisplatin to treat the cells. 24-
hours after drug treating, the full comet assay was performed: the cells were harvested 
by trypsinisation and counted to calculate the volume of cell mix needed to get a total of 
20,000 cells. The samples were centrifuged before removing the supernatant, and the 
resulting cells were embedded onto microscope slides by combining with 1% low 
melting-point agarose. Dilute H2O2 was added to a set of untreated cells to be measured 
as a positive control. Slides were emerged into a pre-made lysis solution (2.5 M Sodium 
Chloride, 0.1 M EDTA (ethylenediaminetetraacetic acid) disodium salt, 10 mM Tris-
Hydrogen Chloride (HCl)), Triton-X-100, and the pH was adjusted to 10 with sodium 
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hydroxide (NaOH)) and incubated for 1-hour at 4C. After incubation, slides were placed 
in pre-chilled electrophoresis solution (0.3 M NaOH, 1 mM EDTA) for 40 minutes at 4C, 
prior to running the samples for electrophoresis at 25V for 30 minutes. The next step was 
neutralisation where the slides were washed with three changes, at 5 minutes each at 
4C, of neutralisation buffer (0.4 M Tris Base, pH 7.5 adjusted with concentrated HCl). 
Finally, the slides were stained with Hoechst (1 µg/ml), covered with a cover slip and left 
to dry at 4C overnight. Analysis was performed using the ZEN Pro software, using a 
magnification of 10x, the DAPI filter, an excitation wavelength of 335-383 nm and an 
emission wavelength of 420-470 nm, on which two different analysis methods were used 
to obtain results.  
 
 
2.8 Clonogenic Assay 
 
The ability of a single cell to form a colony was measured using SVG p12 and U87-
MG cell lines, in both normoxic and hypoxic conditions. The cells were seeded at 1,500 
cells/well in 6-well plates, which were incubated for 24-hours prior to drug treating. Either 
olaparib, TMZ or cisplatin was added to the appropriate wells at a final concentration of 
10 M. Following 4-hours incubation, the EMEM in the wells was discarded and replaced 
with fresh EMEM. After 10-days, media was discarded, and cells were washed with ice 
cold PBS; fixed with 100% ice cold methanol for 10 minutes; and then at room 
temperature stained with crystal violet for 10 minutes. After crystal violet (1%) was 
removed, the wells were washed 3 x with distilled H2O, then left to air dry overnight, 
before the colonies were counted using a digital colony counter. 
 
 
2.9 Statistical Analysis 
 
Statistical analysis was performed in GraphPad Prism software version 5 (GraphPad 
Software, GraphPad Software Inc., USA). An ANOVA (analysis of variance) with a 
Bonferroni’s post hoc test was performed to determine significance with a value of p<0.05 
used to identify significant differences. Appropriate vehicle controls were tested and, 
unless otherwise stated, had no significant effect when compared to the non-treated 
control. To show significance, * indicates comparison to the respective control, † 
indicates comparison between drug treatments (* p<0.05, ** p<0.01, *** p<0.001). Note 
that all data were suppressed as mean ± standard error of the mean (SEM) and, unless 
otherwise specified, of 5 independent repeats.  
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Chapter 3: 
 
 
Results  
 33 
3.1 Growth Curves 
 
The growth of SVG p12 and U87-MG cells, prior to the addition of treatment, was 
determined over 9-days and the data was represented as growth curves (Fig. 3.1A and 
3.1B). The results show that each cell line seems to grow significantly (p<0.05) in 
normoxic conditions compared to in hypoxia, especially from day 5 to day 9. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Graphs showing the growth of SVG p12 (A) and U87-MG cells (B) under 
normoxia (21% O2) and hypoxia (1% O2) without drug treatment. Log phase for SVG p12 
cells commences at day 6 in both normoxia and hypoxia, whereas for U87-MG cells, at 
day 3. For the U87-MG cell line, the log phase finishes at day 8 in both conditions. Data 
are representative of three independent repeats. 
 
 
A 
B 
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3.2 Concentration and Time Responses for Cell Viability  
 
The effect of olaparib, temozolomide and cisplatin on SVG p12 and U87-MG cell 
viability, in both normoxic and hypoxic conditions, was investigated in vitro. All three of 
these treatments produced concentration- and time-dependent changes under both 
conditions (Fig.3.4 and Fig.3.5). TMZ and cisplatin produced a concentration- and time-
dependent decrease in cell viability in both cell lines, and also in both conditions during 
the three time-points, an effect not as clearly observed with olaparib (Fig.3.4A, B; 
Fig.3.5A, B). 
 
 
3.2.1 Effects on Cell Viability in Normoxia 
 
In the concentration range used, olaparib had little effect on cell viability at 24-, 48-, and 
72-hours in either SVG p12 or U87-MG cells under normoxia apart from at 72-hours in 
SVG p12 cells where a significant decrease was observed, when compared to 24-hours, 
at a concentration of 0.1mM (p<0.001) (Fig.3.4A). However, at this 72-hour time-point, 
no significant differences were observed between the SVG p12 and U87-MG cells 
(p>0.05). 
 
TMZ had greater effects on cell viability at all time-points in both cell lines. In SVG p12 
cells after 24-hours, in comparison to 48-hours, no significant differences were observed 
(p>0.05) (Fig.3.4C). However, a significant decrease was observed 72-hours after TMZ 
treatment compared to 24-hours at concentrations of 0.003 mM, 0.1 mM (p<0.01) and 
0.3 mM (p<0.001). 48-hours after TMZ treatment in U87-MG cells, in comparison to 72-
hours in SVG p12 cells, presented a significant decrease in the U87-MG cells at a 
concentration of 0.003 mM (p<0.01). No significant differences were observed in U87-
MG cells at neither 24-, 48- or 72-hours after TMZ treatment (Fig.3.4D), when compared 
to the SVG p12 cells at the equivalent time-points (Fig.3.4C).  
 
Following 48-hours of treatment with cisplatin in SVG p12 cells, a significant difference 
was observed, when compared to 24-hours (Fig.3.4E) at concentrations of 0.01 mM 
(p<0.05), 0.03 mM, 0.1 mM and 0.3 mM (p<0.001). The same significant decrease was 
also observed at 72-hours, in comparison to 24-hours (37.6 M vs. 270.3 M), at the 
same concentrations. In U87-MG cells, the greatest difference observed was at 72-
hours, when compared to 24-hours post-treatment (28.8 M vs. 592.4 M). These 
significantly different decreases occurred at concentrations of 0.01 mM (p<0.05), 0.03 
mM, 0.1 mM and 0.3 mM (p<0.001).  
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Comparisons between TMZ and cisplatin treatments observed various effects on cell 
viability in both cell lines. In SVG p12 cells, the greatest significant decrease was 
observed at 72-hours after treatment with cisplatin, when compared with TMZ (37.6 M 
vs. 244.5 M), at concentrations of 0.03 mM, 0.1 mM and 0.3 mM (p<0.001). In U87-MG 
cells, 72-hours after treatment with TMZ, in comparison to 24-, 48-, and 72-hours after 
treatment with cisplatin, all identified major differences. The greatest significant decrease 
was observed 72-hours after cisplatin treatment compared to TMZ (28.8 M vs. 303.6 
M), at 0.01 mM, 0.03 mM, 0.1 mM and 0.3 mM (p<0.001). 
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Figure 3.2: Original photographs show representative untreated and treated SVG p12 
cells under normoxia (21% O2) after 24-, 48-, and 72-hours following treatment with either 
olaparib, temozolomide or cisplatin using the IC50 values from the cell viability assay. 
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Figure 3.3: Original photographs show representative untreated and treated U87-MG 
cells under normoxia (21% O2) after 24-, 48-, and 72-hours following treatment with either 
olaparib, temozolomide or cisplatin using the IC50 values from the cell viability assay. 
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Figure 3.4: Comparison of the effects of olaparib (A, B), temozolomide (C, D) and 
cisplatin (E, F) on cell viability measured by PrestoBlue assay under normoxia. 
Concentration- and time-dependent changes after drug treatment in both SVG p12 (A, 
C, E) and U87-MG (B, D, F) cell lines in normoxia (21% O2). Data obtained from the 
meanSEM of five consecutive independent repeats. Significant differences are shown 
within each drug treatment: 24-hours compared to 48-hours (+), 24-hours compared to 
72-hours (*).
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Table 3.1: IC50 values for olaparib, temozolomide and cisplatin following 24-, 48-, and 72-hours of treatment in normoxia. Data represent an 
average of five experiments. ANOVA with a Bonferroni’s post hoc test (p<0.05) was performed to show significance. Some of the values, indicated 
in italics, have been predicted by extrapolation from the GraphPad Prism software.  
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.2: IC25 values for olaparib, temozolomide and cisplatin following 24-, 48-, and 72-hours of treatment in normoxia. Data represent an 
average of five experiments. ANOVA with a Bonferroni’s post hoc test (p<0.05) was performed to show significance. Some of the values, indicated 
in italics, have been predicted by extrapolation from the GraphPad Prism software.
 Olaparib Temozolomide Cisplatin 
 24 48 72 24 48 72 24 48 72 
SVG p12 n/a n/a 0.0M n/a 327.4M 244.5M 270.3M 53.4M 37.6M 
U87-MG 15.0mM 5.5M 8.0mM 977.6M 438.6M 303.6M 592.4M 58.1M 28.8M 
 Olaparib Temozolomide Cisplatin 
 24 48 72 24 48 72 24 48 72 
SVG p12 n/a n/a 355.1M 316.0M 241.6M 123.1M 134.5M 25.3M 19.5M 
U87-MG 4.6mM 16.5mM 0.0M 397.1M 153.9M 144.5M 108.3M 12.3M 9.3M 
 40 
3.2.2 Effects on Cell Viability in Hypoxia 
 
The results show that olaparib had little effect overall on cell viability at 24-, 48-, and 72-
hours in SVG p12 and U87-MG cells under hypoxia, apart from at 72-hours in SVG p12 
cells, compared to 24-hours, showed a significant decrease in cell viability (Fig.3.5A), at 
0.01 mM, 0.03 mM (p<0.05), 0.1 mM (p<0.001) and 0.3 mM (p<0.01). In U87-MG cells 
(Fig.3.5B) the greatest significant difference was observed again at 72-hours after 
olaparib treatment, in comparison to 24-hours, at concentrations of 0.1 mM and 0.3 mM 
(p<0.01). 
 
In SVG p12 cells, the greatest significant difference was observed at 72-hours in 
comparison to 24-hours following treatment with TMZ (Fig.3.5C), at concentrations of 
0.01 mM, 0.03 mM (p<0.01), 0.1 mM and 0.3 mM (p<0.001). 48-hours post-treatment 
compared to 72-hours showed no significant differences (p>0.05). Similarly, TMZ in U87-
MG cells caused the largest significant decrease at 72-hours compared to 24-hours 
(Fig.3.5D) at concentrations of 0.3 mM (p<0.01). No significant difference (p>0.05) was 
observed 24-hours post-TMZ treatment when compared to 48-hours, and also when 48-
hours post-treatment was compared to 72-hours (p>0.05). No significant differences 
(p>0.05) were observed between the SVG p12 and U87-MG cells at any time-point. 
 
Following cisplatin treatment, a significant decrease in viability of SVG p12 cells was 
observed at 72-hours in comparison to 24-hours (22.7 M vs. 256.2 M) (Fig.3.5E), at 
concentrations of 0.01 mM, 0.03 mM, 0.1 mM and 0.3 mM (p<0.001). No significant 
difference was seen when comparing 72-hours with 48-hours post-cisplatin treatment 
(p>0.05). In the U87-MG cell line, the largest significant decrease in cell viability was 
observed at 72-hours after drug treatment compared to 24-hours (21.6 M vs. 318.2 M) 
(Fig.3.5F), at concentrations of 0.03 mM, 0.1 mM and 0.3 mM (p<0.001). When SVG 
p12 cells were compared to U87-MG cells, a significant decrease was observed in the 
U87-MG cells at 24-hours following cisplatin treatment (256.2 M vs. 318.2 M) at a 
concentration of 0.03 mM (p<0.05). No significant difference was observed at the other 
time-points (p>0.05).  
 
When TMZ was compared to cisplatin treatment in SVG p12 cells (Fig.3.5C, E), the 
greatest decrease in cell viability was seen 72-hours post-TMZ and cisplatin treatment 
(142.0 M vs. 22.7 M), at concentrations of 0.01 mM, 0.3 mM (p<0.05), 0.03 mM and 
0.1 mM (p<0.001). A significant decrease in cell viability was observed at 48-hours post-
cisplatin treatment in U87-MG cells compared to 72-hours after TMZ treatment (42.9 M 
vs. 209.4 M) (Fig.3.5D, F). This decrease occurred at concentrations of 0.03 mM, 0.1 
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mM (p<0.001). A greater significant decrease was also observed at 72-hours post-
cisplatin treatment when compared to 72-hours post-TMZ treatment (21.6 M vs. 209.4 
M) at concentrations of 0.01 mM (p<0.01), 0.03 mM and 0.1 mM (p<0.001). 
 
 
3.2.3 Comparisons of the Effects on Cell Viability in Normoxia and Hypoxia  
 
Olaparib observed to have a similar efficacy on cell viability in both cell lines when 
normoxia was compared to hypoxia. In the SVG p12 cell line, the largest significant 
difference was observed at 24-hours after treatment, when normoxia was compared to 
hypoxia; this was at concentrations of 0.03 mM (p<0.01) and 0.3 mM (p<0.05). No 
significant difference was seen when comparing 48- and 72-hours after treatment, in the 
SVG p12 cells (p>0.05) (Fig.3.4A and Fig.3.5A). In the U87-MG cells, no significant 
difference was observed at 24-, 48- nor 72-hours. 
 
No significant differences were observed in cell viability following TMZ and cisplatin 
treatment at 24-, 48-, or 72-hours  in SVG p12 or U87-MG cells when the two conditions 
were compared (p>0.05).  
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Figure 3.5: Comparison of the effects of olaparib (A, B), temozolomide (C, D) and 
cisplatin (E, F) on cell viability measured by PrestoBlue assay under hypoxia. 
Concentration- and time-dependent changes after drug treatment in both SVG p12 (A, 
C, E) and U87-MG (B, D, F) cell lines in hypoxia (1% O2). Data obtained from the 
meanSEM of five consecutive independent repeats. Significant differences are shown 
within each drug treatment: 24-hours compared to 72-hours (*).
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Table 3.3: IC50 values for olaparib, temozolomide and cisplatin following 24-, 48-, and 72-hours of treatment in hypoxia. Data represent an average 
of five experiments. ANOVA with a Bonferroni’s post hoc test (p<0.05) was performed to identify significance. Some of the values, indicated in 
italics, have been predicted by extrapolation from the GraphPad Prism software. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.4: IC25 values for olaparib, temozolomide and cisplatin following 24-, 48-, and 72-hours of treatment in hypoxia. Data represent an average 
of five experiments. ANOVA with a Bonferroni’s post hoc test (p<0.05) was performed to identify significance. Some of the values, indicated in 
italics, have been predicted by extrapolation from the GraphPad Prism software.
 Olaparib Temozolomide Cisplatin 
 24 48 72 24 48 72 24 48 72 
SVG p12 n/a n/a n/a n/a 252.9M 
 
142.0M 
 
256.2M 55.9M 
 
22.7M 
U87-MG n/a n/a 1.8mM 348.7M 284.7M 209.4M 318.2M 42.9M 21.6M 
 Olaparib Temozolomide Cisplatin 
 24 48 72 24 48 72 24 48 72 
SVG p12 n/a n/a 1.3mM 309.8M 145.6M 67.4M 130.2M 23.5M 8.9M 
U87-MG n/a n/a 543.3M 
 
278.2M 
 
179.0M 
 
118.6M 
 
75.6M 
 
13.4M 9.4M 
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3.3 Cell Proliferation 
 
Based on the IC25 values obtained from the cell viability assay, the effect of drug 
treatment on cell proliferation was investigated in vitro under normoxic and hypoxic 
conditions using CFDA-SE incorporation and flow cytometric analysis. Figure 3.6 shows 
representative graphs of the right-to-left shift in cell proliferation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6: Original representative graphs showing the right-to-left in cell proliferation of 
U87-MG cells measured by CFDA-SE staining and analysed by flow cytometry. (A) 
normoxia (21% O2), (B) hypoxia (1% O2). These original graphs are typical of 5 different 
experiments using U87-MG cells. 
 
 
3.3.1 Effects on Cell Proliferation in Normoxia 
 
In each drug treatment, a time-dependent decrease in CFDA-SE fluorescence was 
observed under normoxia, indicating proliferation is occurring. In SVG p12 cells, little 
difference was observed in proliferation at 24-, 144-, and 168-hours between the control 
and all drug treatments (24h: 478% vs. olaparib 4615%; TMZ 406%; cisplatin 468%) 
(144h: 31% vs. 31%; 42%; 41%) (168h: 21% vs. 00%; 21%; 11%) (Fig.3.7A). 
However, while TMZ and cisplatin treated cells were similar to the control at 48- and 72-
hours, it was observed that olaparib treatment may have slowed proliferation as an 
increase in CFDA-SE fluorescence was observed (48h: 174% vs. 3212%) (72h: 62% 
vs. 175%). However, these effects were not significant (p>0.05).  
 
In U87-MG cells, olaparib caused a significant increase in CFDA-SE fluorescence at 24-
hours, when compared to the control treatment (5615% vs. 2417%) (p<0.01) 
(Fig.3.7B). Cisplatin was also observed to cause an increase in fluorescence at 24-hours, 
compared to the control, though this effect was not significant (p>0.05). A slower rate of 
proliferation was observed between the control and all drug treatments at 48-hours 
A B 
0hr 168hr 0hr 168hr 
 45 
(197% vs. olaparib 3110%; TMZ 368%; cisplatin 3617%). While TMZ treated cells 
were similar to the control at 72-hours, olaparib and cisplatin induced an increase in 
CFDA-SE fluorescence (85% vs. 2114%; 2615%). Though these results were not 
significant (p>0.05).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7: Bar charts showing a comparison of the effects of olaparib, temozolomide 
and cisplatin on cell proliferation measured by CFDA-SE fluorescence under normoxia. 
CFDA-SE fluorescence presented as a percentage of the respective control after drug 
treatment in normoxic conditions (21% O2). (A) SVG p12, (B) U87-MG. Data represent 
meanSEM of five independent repeats with significance determined by ANOVA. 
Significant difference (p<0.05) shown by asterisk (*) is in comparison to the respective 
control. 
 
 
 
 
 
 
 
A 
B 
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3.3.2 Effects on Cell Proliferation in Hypoxia 
 
In hypoxic conditions, for each drug treatment a time-dependent decrease in CFDA-SE 
fluorescence was observed, signifying that cell proliferation is occurring. In SVG p12 
cells, little difference in proliferation was observed at 48-, 72-, 144-, and 168-hours 
between the non-treated control and all the drug treatments (Fig.3.8A). However, while 
TMZ-treated SVG p12 cells were similar to the control at 24-hours, olaparib caused an 
increase in CFDA-SE fluorescence (262% vs. 337%), though this effect was not 
significant (p>0.05). Cisplatin produced a significant increase at 24-hours (398%) 
(p<0.05), when compared to the control. At 24-hours, a significant increase in 
fluorescence was also observed between cisplatin and TMZ treatment (39%8% vs. 
263%) (p<0.05). 
 
In U87-MG cells, little difference was observed in proliferation at 144- and 168-hours 
between the non-treated control and all drug treatments (144h: 10% vs. olaparib 10%; 
TMZ 11%; cisplatin 21%) (168h: 10% vs. 10%; 10%; 10%) (Fig.3.8B). Olaparib 
was observed to cause a decrease in CFDA-SE fluorescence at 24-hours, when 
compared to the control (2010% vs. 2815%), though this effect was not significant 
(p>0.05). While olaparib treated cells were similar to the control at 48- and 72-hours, 
TMZ caused an increase in fluorescence at 48-hours (114% vs. 175%) and cisplatin 
caused an increase at 48- and 72-hours (48h: 175%) (72h: 43% vs. 118%).  
 
 
 
3.3.3 Comparisons on Cell Proliferation in Normoxia and Hypoxia 
 
Olaparib was observed to have similar efficacy overall on cell proliferation in both cell 
lines under hypoxia compared to normoxia. A significant effect was seen in the olaparib 
treated U87-MG cells in hypoxia, compared to normoxia. Though, the highest difference 
was present at 24-hours post-treatment (2010% vs. 56%15%) (p<0.01).  
 
No significant differences were observed on cell proliferation following TMZ and cisplatin 
treatment at 24-, 48-, 72-, 144- or 168-hours  in SVG p12 or U87-MG cells when the two 
conditions were compared (p>0.05).  
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Figure 3.8: Bar charts showing a comparison of the effects of olaparib, temozolomide 
and cisplatin on cell proliferation measured by CFDA-SE fluorescence under hypoxia. 
CFDA-SE fluorescence presented as a percentage of the respective control after drug 
treatment in hypoxic conditions (1% O2). (A) SVG p12, (B) U87-MG. Data represent 
meanSEM of five independent repeats with significance determined by ANOVA. 
Significant difference (p<0.05) shown by the asterisk (*) is in comparison to the 
respective control, and † denotes significance between drug treatments. 
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3.4 Cell Cycle Analysis 
 
Based on the IC25 values obtained from the cell viability assay, the effect of drug 
treatment on cell cycle arrest was investigated in vitro under normoxic and hypoxic 
conditions using PI incorporation and flow cytometric analysis. Figure 3.9 represents 
illustrative graphs of cell cycle arrest for the three drug treatments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9: Original representative graphs of cell cycle distribution for each treatment in 
U87-MG cells measured by PI staining and analysed by flow cytometry. (A) normoxia 
(21% O2), (B) hypoxia (1% O2). Graphs are typical of 5 such different experiments. 
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3.4.1 Cell Cycle Analysis in Normoxia 
 
The control and all three of the drug treatments caused the SVG p12 and U87-MG cells 
to arrest during one of the four phases of the cell cycle. Even though many statistically 
significant differences were not observed, variances between the four treatments were 
present in normoxia (Fig.3.10). 
 
In SVG p12 cells, a decrease in the proportion of cells in the G0/G1 phase of the cell 
cycle was observed following drug treatment with olaparib (286%) and TMZ (293%) 
when compared to control (424%), although these differences were not significant 
(p>0.05) (Fig.3.10A). In contrast, cisplatin treatment had no effect on the proportion of 
cells in G0/G1 (4210%), compared to control. Interestingly, following 48-hours of drug 
treatment, no change in the proportion of cells found in S phase of the cell cycle was 
observed when compared to control. Changes were observed in G2/M phase, where in 
comparison to control (425%), both TMZ (509%) and olaparib (539%) increased the 
population size, however, the data were not significant. Interestingly, cisplatin (3412%) 
decreased the proportion of cells in G2/M phase compared to the control, but it did 
increase the population undergoing apoptosis (74%) when compared to control (33%). 
 
In U87-MG cells, a decrease in the population of cells in the G0/G1 phase of the cell 
cycle was observed following drug treatment with olaparib (334%) (p<0.05), TMZ 
(407%) and cisplatin (384%), when compared to the control (515%) (Fig.3.10B). No 
real change was observed in the proportion of cells found in the S phase for all drug 
treatments when compared to the control. An increase was observed in the proportion 
of cells in the G2/M phase following 48-hours of treatment with olaparib (506%) 
(p<0.001), TMZ (3710%) and cisplatin (395%) when compared to the control (286%).  
 
When compared to the non-treated control, all drug treatments appeared to cause cell 
cycle arrest during the G2/M phase in both cell lines, apart from cisplatin in the SVG p12 
cells. Overall, olaparib induced the greatest effect in both cell lines compared to TMZ 
and cisplatin. 
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Figure 3.10: Bar charts show comparisons of olaparib, temozolomide and cisplatin on 
cell cycle arrest measured by PI fluorescence under normoxia. Cell cycle arrest analysis 
are presented as a percentage of the respective control following 48-hours after drug 
treatment in normoxic conditions (21% O2). (A) SVG p12, (B) U87-MG. Data represent 
meanSEM of five consecutive independent repeats with significance determined by 
ANOVA. Significant differences (p<0.05) shown by the asterisks (*) is in comparison to 
the respective control. 
 
 
 
 
 
 
 
 
 
 
 
A 
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3.4.2 Cell Cycle Analysis in Hypoxia 
 
Various differences of the control treatment and the drug treatments in the SVG p12 and 
U87-MG cells on cell cycle arrest were observed following 48-hours of drug treatment in 
hypoxic conditions. 
 
In SVG p12 cells, a decrease in cell cycle analysis was observed in the population of 
cells in the G0/G1 phase of the cell cycle following drug treatment with olaparib (327%), 
TMZ (373%) and cisplatin (3112%) when compared to the control (424%), although 
these differences were not significant (p>0.05) (Fig.3.11A). A decrease in the G2/M 
population was observed following TMZ treatment (3511%) when compared to the 
control (467%). In contrast, no effect was observed on the proportion of cells in G2/M 
after treatment with olaparib (4916%) and cisplatin (4818%), when compared to the 
control. Changes were observed in apoptosis, where in comparison to the control 
(00%), both olaparib (66%) and TMZ (55%) increased the population size, although 
non-significantly. 
 
In the U87-MG cells, a decrease in the proportion of cells in the G0/G1 phase of the cell 
cycle was observed following olaparib (5811%), TMZ (548%) and cisplatin (306%) 
(p<0.001) treatments, when compared to the control (653%) (Fig.3.11B). A small 
decrease was also observed in the population of cells in the S phase following treatment 
with olaparib (141%) and TMZ (152%), compared to the control (171%). Changes 
were observed in the G2/M phase, where in comparison to control (182%), olaparib 
(2811%), TMZ (2811%) and cisplatin (508%) (p<0.01) increased the population size. 
Interestingly, only cisplatin (43%) increased the apoptotic population of cells, compared 
to control (00%), although the data were not significant. A significant decrease was 
observed in the proportion of U87-MG cells in the G0/G1 phase following treatment with 
cisplatin (306%), in comparison to olaparib (5811%) (p<0.01) and TMZ (548%) 
(p<0.05). 
 
All drug treatments induced cell cycle arrest in the G2/M phase in SVG p12 and U87-MG 
cells, with the exception of TMZ in SVG p12 cells. 
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3.4.3 Comparisons of Cell Cycle Distribution in Normoxia and Hypoxia  
 
When comparing the two conditions, it was observed that the results were quite similar, 
with cell cycle arrest in the G2/M phase seeming to be the main effect of drug treatment. 
In contrast to cell viability, olaparib was similar in efficacy to TMZ and cisplatin 
treatments. In addition to cell cycle arrest, some results indicate the induction of 
apoptosis, following 48-hours of drug treatment with IC25 concentrations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11: Bar charts showing comparisons of olaparib, temozolomide and cisplatin 
on cell cycle arrest measured by PI fluorescence under hypoxia. Cell cycle arrest 
analysis presented as a percentage of the respective control following 48-hours after 
drug treatment in hypoxic conditions (1% O2). (A) SVG p12, (B) U87-MG. Data represent 
meanSEM of five consecutive independent repeats with significance determined by 
ANOVA. Significant differences (p<0.05) shown by the asterisks (*) is in comparison to 
the respective control, and † denotes significance between drug treatments. 
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3.5 Apoptosis Assay 
 
Using the IC50 values of the three drug treatments (Table 3.1 and 3.3) obtained from 
the cell viability assay, detection of apoptosis based on the changes that occur in the 
permeability of cell membranes was investigated in vitro, under normoxic and hypoxic 
conditions using PI and Annexin V incorporation and flow cytometric analysis. Figure 
3.12 illustrates representative graphs of apoptotic analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12: Original representative graphs of apoptosis analysis for cisplatin treatment 
in U87-MG cells measured by PI and Annexin V staining and analysed by flow cytometry.  
(A) normoxia (21% O2), (B) hypoxia (1% O2). Graphs are typical of 5 such different 
experiments.  
 
 
 
3.5.1 Detection of Apoptosis in Normoxia 
 
Across each timepoint, neither olaparib nor TMZ had any effect on apoptosis in SVG p12  
cells when compared to control (Fig.3.13A, B, C). For example, at 72-hours, the 
proportion of live (375%) versus apoptotic (446%) cells in control was similar to that 
following treatment with olaparib (333% and 487%, respectively) and TMZ (335% 
and 4411%, respectively). In contrast, cisplatin increased the proportion of apoptotic 
cells (5510% at 24-hours, 703% at 48-hours and 631% at 72-hours) over time in 
comparison to control (5110%; 624%; 446%), with a significant increase at 72-hours 
(p<0.05). While a small increase in the proportion of apoptotic cells was observed 
A B 
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following treatment with the combination of olaparib and TMZ (5710% at 24-hours, 
683% at 48-hours and 557% at 72-hours) compared to control (5110% at 24-hours, 
624% at 48-hours and 446% at 72-hours), the most significant effect was with the 
combination of olaparib and cisplatin, with apoptotic populations significantly increased 
compared to control at 48- (743%) (p<0.05) and 72-hours (662%) (p<0.01). 
 
A similar pattern of effect was observed in U87-MG cells (Fig.3.14A, B, C), however there 
was little effect of the drug treatments at 24-hours. Cisplatin (233%), olaparib and TMZ 
(233%) and olaparib and cisplatin (223%) increased the population of apoptotic cells 
at 48-hours, when compared to the control (162%). Significant changes were observed 
at 72-hours for cisplatin alone and when combined with olaparib. A significant decrease 
was observed in the population of live cells following drug treatment with cisplatin 
(703%) (p<0.001) and olaparib and cisplatin combined (722%) (p<0.01), in 
comparison to the control (832%). In contrast, a significant increase in the proportion of 
apoptotic cells was observed following cisplatin (244%) (p<0.01) and olaparib and 
cisplatin combined (223%) (p<0.05) compared to the control (131%).  
 
The population of live U87-MG cells significantly decreased following drug treatment with 
cisplatin (703%), in comparison to olaparib (811%) and TMZ (822%) (p<0.01). A 
significant increase was also observed following cisplatin (244%) treatment in the 
apoptotic populations, when compared to olaparib (151%) (p<0.05) and TMZ (131%) 
(p<0.01). Similarly, the combination treatment of olaparib and cisplatin (722%) induced 
a significant decrease in the proportion of live cells, compared to olaparib (811%) 
(p<0.05). Essentially, cisplatin was more effective than either olaparib or TMZ as a 
monotherapy.  
 
When SVG p12 cells were compared to U87-MG cells, a similar pattern was observed 
where the same drug treatments were effective in both cell lines. A higher proportion of 
apoptosis was observed in the non-treated control in SVG p12 cells compared to U87-
MG cells.  
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Figure 3.13: Bar charts showing comparisons of various drug treatments on the effects 
of apoptosis measured by PI and Annexin V fluorescence under normoxia in SVG p12 
cells. Apoptotic analysis presented as a percentage of the total following (A) 24-, (B) 48-
, and (C) 72-hours after single/combined drug treatment in normoxia (21% O2). Data 
represent meanSEM of five independent repeats with significance determined by 
ANOVA. Significant differences (p<0.05) shown by the asterisks (*) is in comparison to 
the respective control, and † denotes significance between drug treatments. 
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Figure 3.14: Bar charts showing comparisons of various drug treatments on the effects 
of apoptosis measured by PI and Annexin V fluorescence under normoxia in U87-MG 
cells. Apoptotic analysis presented as a percentage of the total following (A) 24-, (B) 48-
, and (C) 72-hours after single/combined drug treatment in normoxia (21% O2). Data 
represent meanSEM of five independent repeats with significance determined by 
ANOVA. Significant differences (p<0.05) shown by the asterisks (*) is in comparison to 
the respective control, and † denotes significance between drug treatments. 
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3.5.2 Detection of Apoptosis in Hypoxia 
 
A similar pattern was observed in SVG p12 cells as in normoxia. However, combination 
treatments had the largest effect and were most consistent, as well as cisplatin. While 
the other drug treatments had little effect at 24-hours (Fig.3.15A), the combination 
treatment with olaparib and cisplatin (584%) caused a significant increase in the 
apoptotic population compared to the control (445%) (p<0.05). Cisplatin (634%) 
(p<0.05), olaparib and TMZ combined (633%) (p<0.05) and olaparib and cisplatin 
combined (653%) (p<0.01) all induced a significantly increased proportion of apoptotic 
cells at 48-hours, in comparison to the control (523%) (Fig.3.15B). Interestingly, all drug 
treatments were effective at 72-hours compared to the non-treated control, though not 
all were significant (Fig.3.15C). The population of apoptotic cells following treatment with 
cisplatin (624%) (p<0.05), olaparib and TMZ combined (663%) (p<0.01) and olaparib 
and cisplatin combined (642%) (p<0.05) caused a significant increase, compared to the 
control (498%). The combination treatment of olaparib and TMZ also caused a 
significant increase in the proportion of apoptotic cells at 72-hours when compared to 
olaparib (543%) (p<0.05).  
 
In the U87-MG cells, again no change was observed at 24-hours following drug 
treatment. Only cisplatin and olaparib and cisplatin combined induced any effect at 48- 
and 72-hours, although, no significant differences were present between them (p>0.05). 
 
When comparing the cell lines, the same results that were obtained in normoxia were 
observed in hypoxia; with similar patterns for all drug treatments and the proportion of 
apoptotic cells observed for the non-treated control was higher in SVG p12 cells.  
 
 
3.5.3 Comparisons of Apoptosis in Normoxia and Hypoxia 
 
Cisplatin was observed to be the most consistent monotherapy with similar efficacy in 
both conditions, although not significant in U87-MG cells in hypoxia at 72-hours. The 
combination treatments were the most effective, though again without significance in the 
U87-MG cells under hypoxia. 
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Figure 3.15: Bar charts showing comparisons of various drug treatments on the effects 
of apoptosis measured by PI and Annexin V fluorescence under hypoxia in SVG p12 
cells. Apoptotic analysis presented as a percentage of the total following (A) 24-, (B) 48- 
and (C) 72-hours after single/combined drug treatment in hypoxia (1% O2). Data 
represent meanSEM of five independent repeats with significance determined by 
ANOVA. Significant differences (p<0.05) shown by the asterisks (*) is in comparison to 
the respective control, and † denotes significance between drug treatments. 
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Figure 3.16: Bar charts showing comparisons of various drug treatments on the effects 
of apoptosis measured by PI and Annexin V fluorescence under hypoxia in U87-MG 
cells. Apoptotic analysis presented as a percentage of the total following (A) 24-, (B) 48- 
and (C) 72-hours after single/combined drug treatment in hypoxia (1% O2). Data 
represent meanSEM of five independent repeats with significance determined by 
ANOVA. Note no significant differences were observed (p>0.05). 
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3.6 Autophagy Assay 
 
Based on the IC50 values obtained from the cell viability assay, the effects on the 
induction of autophagy following drug treatment were investigated under normoxic and 
hypoxic conditions in vitro. A combination treatment of rapamycin and chloroquine was 
used as a positive control. Figure 3.17 illustrates representative graphs for autophagic 
fluorescence following 24-hours of drug treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.17: Original representative graphs for autophagy following treatment with non-
treated control (red), olaparib (green), temozolomide (blue), cisplatin (purple), olaparib 
and temozolomide (pink), olaparib and cisplatin (orange) and the positive control (yellow) 
in U87-MG cells measured by CYTO-ID green staining and analysed by flow cytometry.  
(A) normoxia (21% O2), (B) hypoxia (1% O2). Graphs are typical of 5 such different 
experiments. 
A 
B 
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3.6.1 Effects on Autophagy in Normoxia 
 
In SVG p12 cells, it was clearly visible that the positive control treatment of rapamycin 
and chloroquine worked effectively, when compared to the control with a percentage 
increase of 9521% (p<0.001) (Fig.3.18A). Overall, a similar pattern to the apoptosis 
assay was observed, in which cisplatin (1135%) and the combination treatments of 
olaparib and TMZ (13015%) and olaparib and cisplatin (1225%) appear to have 
increased autophagy, with maybe a small effect of olaparib (1076%), when compared 
to the non-treated control (1000%). Interestingly, a significant increase was observed 
in autophagy induction by olaparib and TMZ combination treatment (13015%) in 
comparison to TMZ alone (915%) (p<0.05). 
 
In U87-MG cells, the positive control treatment also induced a significant increase in 
autophagy, when compared to the non-treated control as there was a percentage 
increase of 12327% (p<0.001) (Fig.3.18B). The greatest effects on autophagy were 
observed following treatment with olaparib (1145%), olaparib and TMZ combined 
(1369%) and olaparib and cisplatin combined (12010%), when compared to the 
control (1000%), although these differences were not significant.  
 
Comparisons between SVG p12 and U87-MG cells showed a similar pattern of results, 
although cisplatin monotherapy induced no autophagy in U87-MG cells. The combination 
treatments were observed to induce the greatest effects on autophagy.  
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Figure 3.18: Bar charts showing comparisons of various drug treatments on autophagy 
induction as measured by CYTO-ID green stain fluorescence under normoxia. 
Autophagic fluorescence presented as a percentage of the respective control following 
24-hours after single/combined drug treatment in normoxia (21% O2). (A) SVG p12, (B) 
U87-MG. Data represent meanSEM of five independent repeats with significance 
determined by ANOVA. Significant differences (p<0.05) shown by the asterisks (*) is in 
comparison to the respective control, and † denotes significance between drug 
treatments. 
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3.6.2 Effects on Autophagy in Hypoxia 
 
In SVG p12 cells, the rapamycin and chloroquine treatment caused an increase of 
7120% in comparison to the control (1000%) (p<0.001), indicating the positive control 
has worked (Fig.3.19A). While an increase in autophagy was observed following 
treatment with the combination of olaparib and cisplatin (13710%) compared to the non-
treated control, the most significant effect was with the combination of olaparib and TMZ, 
where autophagy was significantly increased (1579%) (p<0.01). An increase in 
autophagy was also observed with olaparib (1015%) and cisplatin (10310%) in 
comparison to the control, although not significant. In contrast, TMZ (884%) caused a 
decrease in autophagy when compared to the control. A significant increase was induced 
by the combination treatments of olaparib and TMZ (1579%) (p<0.01) and olaparib and 
cisplatin (13710%) (p<0.05), compared to olaparib monotherapy (1015%). 
 
In U87-MG cells, the positive control treatment induced an increase of 15024% 
compared to the control (1000%) (p<0.001) (Fig.3.19B). The combination treatments of 
olaparib and TMZ (15711%) (p<0.001) and olaparib and cisplatin (15411%) (p<0.01) 
caused a significant increase in autophagy, in comparison to the control. Olaparib 
(1127%), TMZ (1024%) and cisplatin (1154%) also caused an increase in autophagy, 
although they were not significant (p>0.05). Olaparib in the combination treatments was 
significantly better than olaparib on its own. A significant increase was induced by 
olaparib and TMZ (15711%) (p<0.01) and olaparib and cisplatin (15411%) (p<0.05), 
in comparison to olaparib monotherapy (1127%).  
 
Comparisons between SVG p12 and U87-MG cells showed a similar pattern of results, 
although this time, cisplatin monotherapy may have induced an effect in U87-MG cells 
(1154%), when compared to SVG p12 cells (10310%). The combination treatments 
had the greatest effects in both cell lines.  
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Figure 3.19: Bar charts showing comparisons of various drug treatments on the 
induction of autophagy as measured by CYTO-ID green stain fluorescence under 
hypoxia. Autophagic fluorescence presented as a percentage of the respective control 
following 24-hours after single/combined drug treatment in hypoxia (1% O2). (A) SVG 
p12, (B) U87-MG. Data represent meanSEM of five independent repeats with 
significance determined by ANOVA. Significant differences (p<0.05) shown by the 
asterisks (*) is in comparison to the respective control, and † denotes significance of 
olaparib compared to the other drug treatments. 
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3.6.3 Comparisons of the Effects of Autophagy in Normoxia and Hypoxia 
 
When SVG p12 cells, in the two conditions, were compared, less autophagy was 
observed under hypoxia, apart from the combination treatments which caused an 
increase in autophagy under hypoxia (Fig.3.20A). Olaparib and TMZ combined and 
olaparib and cisplatin combined induced an increase in autophagy under hypoxia 
(14519% and 13121%, respectively) compared to normoxia (13015% and 1225%, 
respectively). Overall, all drug treatments had a similar efficacy.  
 
In the U87-MG cells, similar levels of autophagy were observed in both conditions. The 
monotherapies all had a similar efficacy, whereas the combination treatments may be 
more effective under hypoxia. While olaparib and TMZ combined increased autophagy 
in hypoxia (15824%) compared to normoxia (1369%), the greatest effect was 
observed with the combination of olaparib and cisplatin with a significant increase in 
autophagy under hypoxia (15523%) in comparison to normoxia (12010%) (p<0.05). 
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Figure 3.20: Bar charts showing comparisons of the drug treatments on the induction of 
autophagy as measured by CYTO-ID green stain fluorescence under normoxia and 
hypoxia. Effects on autophagy showing the comparisons following 24-hours after 
single/combined drug treatment in normoxia (21% O2) and hypoxia (1% O2). (A) SVG 
p12, (B) U87-MG. Data represent meanSEM of five independent repeats with 
significance determined by ANOVA. Significant difference (p<0.05) shown by † denotes 
significance within the combination drug treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
A 
B 
†
† 
 67 
3.7 Comet Assay 
 
Based on the IC50 values, the proportion of DNA damage caused following drug 
treatment was investigated in vitro. Figure 3.21 illustrates representative images that 
were observed after electrophoresis. Two sets of analysis were performed: total 
intensity/area and the average intensity/unit distance. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.21: Original representative images that were observed following treatment with 
non-treated control (A, B) and olaparib (C, D) in U87-MG cells, measured by 
electrophoresis. The two methods of analysis used are shown: total intensity/area (m2) 
(A, C) and average intensity/unit distance (m) (B, D). Images are typical of 3 such 
different experiments. 
 
 
 
3.7.1 Analysis of the Total Intensity/Area 
 
When the control treatment was compared to the drug treatments in the SVG p12 cells, 
a range of differences were observed (Fig.3.22A). The positive control of H2O2 (832) 
caused a significant increase in the total intensity/area of the tail, compared to the 
negative control (387) (p<0.001), and also a significant decrease in the head (232 vs. 
786) (p<0.001). Similar significance was also observed with TMZ (tail: 748) (head: 
315) (p<0.001). Olaparib caused a decrease in intensity for both the tail (356) and 
head (714), when compared to the control, although this was not significant. Cisplatin 
produced an increase in the total intensity/area in the tail (485), but a decrease in the 
comet head (732), in comparison to the control. 
A B 
C D 
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Olaparib (356) caused a significant decrease in the intensity/area of the tail, when 
compared to H2O2 (832) (p<0.001). Whereas, a significant increase occurred in the 
comet head (714 vs. 232) (p<0.001). A similar result was present when olaparib was 
compared to TMZ where significant differences were observed in both the tail (356 vs. 
748), and the comet head (714 vs. 315) (p<0.001). A significantly lower intensity/area 
was produced by olaparib in the comet tail, when compared to cisplatin (485) (p<0.05). 
H2O2 and TMZ also caused great significant differences when compared to cisplatin. 
Similarly, a significant decrease in intensity/area was produced in the tail following 
cisplatin treatment (p<0.001), and a significantly greater intensity/area was seen in the 
head (p<0.001).  
 
In U87-MG cells, when the control treatment was compared to H2O2, a significant 
decrease in the total intensity/area in the tail (444 vs. 863) (p<0.001), and a significant 
increase in the head (794 vs. 211) (p<0.001) was observed (Fig.3.22B). Similar results 
were observed when the control treatment was compared to TMZ (tail: 726) (head: 
314) (p<0.001). A significantly lower intensity/area was produced with cisplatin 
treatment in the comet tail, in comparison to the control (00) (p<0.001). Whereas, a 
significantly greater effect was seen in the comet head (1000) (p<0.01). Olaparib 
caused an insignificant decrease in both the comet tail (372) and head (712), 
compared to the control.  
 
A significantly lower value for the total intensity/area was produced by olaparib in the tail, 
when compared to H2O2 (372 vs. 863) (p<0.001). However, a significant increase was 
present in the head (712 vs. 211) (p<0.001). Major significant differences were also 
observed when olaparib was compared to TMZ and cisplatin treatment. A significant 
decrease in the intensity/area of the tail in olaparib, compared to TMZ (726), and a 
significant increase in the head (314) (p<0.001). Whereas, olaparib compared to 
cisplatin caused a significantly greater intensity/area in the tail (00), and a significant 
decrease in the head (1000) (p<0.001). H2O2 also produced significant differences 
when compared to TMZ and cisplatin. TMZ caused a minor, but significant decrease in 
the intensity/area in the comet tail, in comparison to H2O2 (p<0.05). Cisplatin produced a 
significant decrease in the tail, and a significant increase in the head (p<0.001). 
Significant differences were also present when TMZ was compared with cisplatin; a 
significant increase in the tail, and a significant decrease in the comet head (p<0.001).  
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Olaparib treatment in either the U87-MG cells (tail: 372, head: 712) or the SVG p12 
cells (tail: 356, head: 713) did not produce a significant difference in either the comet 
tail or head fluorescence intensity. Minor differences were also observed with TMZ in 
both of the cell lines; with a decrease in intensity/area in the tail, but an increase in the 
head of U87-MG cells, in comparison to SVG p12 cells. Cisplatin, however, caused a 
significant decrease in the comet tail, and a significant increase in the comet head of 
U87-MG cells compared to SVG p12 (p<0.001).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.22: Bar charts showing comparisons of the proportion of DNA damage caused 
following drug treatment measured by electrophoresis. Effects of drug treatment 
presented by the total intensity/area (m2). (A) SVG p12, (B) U87-MG. Data represent 
meanSEM of three consecutive independent repeats with significance determined by 
ANOVA. Significant differences (p<0.05) shown by the asterisks (*) is in comparison to 
the respective control, and † denotes significance of olaparib only compared to the other 
drug treatments. 
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3.7.2 Analysis of the Average Intensity/Unit Distance 
 
In SVG p12 cells, when the control treatment was compared to the other drug treatments 
various differences were observed (Fig.3.23A). The control, compared to the positive 
control of H2O2, showed a significant increase in the average intensity/unit distance in 
the comet head (323 vs. 206) (p<0.01). A greater significant increase was also caused 
by the control in the comet head, when compared to TMZ (172) (p<0.001). A decrease 
in average intensity/distance was produced by olaparib in the comet head (266), in 
comparison to the control, though not significant. 
 
H2O2 caused a significant decrease in the average intensity/distance in the comet head, 
when compared to cisplatin (208 vs. 316) (p<0.01). While no significance was present 
when H2O2 and cisplatin was compared to olaparib (p>0.05), a significantly greater 
average intensity/distance was observed with olaparib in the comet head, when 
compared to TMZ (266 vs. 172) (p<0.05). TMZ produced a significantly lower average 
intensity/distance in the comet head, than cisplatin (316) (p<0.001).  
 
Several variations were also present in the U87-MG cells following 24-hours of drug 
treatment (Fig.3.23B). When the control treatment was compared to the positive control, 
olaparib and TMZ, no significant differences in average intensity/unit distance were 
observed (p>0.05). However, when compared to cisplatin, a significant increase in the 
comet head was present (285 vs. 567) (p<0.001).  
 
Olaparib caused no difference in the average intensity/distance in the comet tail but did 
cause a small but non-significant decrease in the comet head, when compared to TMZ 
(tail: 51 vs. 51) (head: 213 vs. 231), though these differences were not significant. 
Cisplatin produced significantly greater results in the comet head, when compared to all 
drug treatments (567 vs H2O2 247; olaparib 213; TMZ 231) (p<0.001).  
 
The average intensity/unit distance of the comet tail and head produced by olaparib in 
U87-MG cells was lower than in SVG p12 cells (tail: 61 vs. 51) (head: 213 vs. 266). 
TMZ treatment in U87-MG cells caused an increase in the comet head compared to SVG 
p12 cells (231 vs. 172). Cisplatin produced a significant decrease in the average 
intensity/distance of the tail in U87-MG cells, compared to SVG p12 cells (00 vs. 92) 
(p<0.05). Whereas, a significant increase of the head was produced in U87-MG cells 
(567 vs. 316) (p<0.001).  
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Figure 3.23: Bar charts showing comparisons of the proportion of DNA damage caused 
following drug treatment measured by electrophoresis. Effects of drug treatment 
presented by the average intensity/unit distance (m). (A) SVG p12, (B) U87-MG. Data 
represent meanSEM of three consecutive independent repeats with significance 
determined by ANOVA. Significant difference (p<0.05) shown by the asterisk (*) is in 
comparison to the respective control, and † denotes significance of olaparib  compared 
to the other drug treatments. 
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3.8 Clonogenic Assay 
 
Following 10-days of drug treatment in both normoxic and hypoxic conditions, 
colonies for each treatment in SVG p12 and U87-MG cells were visually counted and 
recorded. 
 
 
3.8.1 Clonogenic Analysis in Normoxia 
 
No significant differences (p>0.05) were observed in either of the cell lines in normoxia, 
though many variations were observed. In SVG p12 cells (Fig.3.24A), olaparib (836%) 
had the greatest effect by producing a lower number of colonies, when compared to the 
control (1000%). Whereas, the results for TMZ and cisplatin were similar to the control.  
 
However, in U87-MG cells (Fig.3.24B), when compared to the control all drug treatments 
caused a decrease in the number of colonies (1000% vs. olaparib 7615%; TMZ 
6013%; cisplatin 5013%).  
 
When the two cell lines were compared, olaparib induced a consistent decrease in 
colonies, but cisplatin induced the greatest effect in U87-MG (5013%) compared to 
SVG p12 cells (10025%). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.24: Bar charts showing comparisons of the quantity of colonies visualised 
following drug treatment under normoxia. The quantity of colonies observed presented 
as a percentage of the respective control following 10-days after drug treatment in 
normoxia (21% O2). (A) SVG p12, (B) U87-MG. Data represent meanSEM of five 
consecutive independent repeats. Note no significant differences were observed 
(p>0.05). 
A B 
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3.8.2 Clonogenic Analysis in Hypoxia 
 
In SVG p12 cells (Fig.3.25A), following drug treatment with olaparib (906%), TMZ 
(888%) and cisplatin (796%), all treatments produced small decreases in colony 
number, compared to the control (1000%). Whereas, in U87-MG cells (Fig.3.25B), 
interestingly olaparib (1036%) had no effect on colony number in comparison to the 
control (1000%). When comparing the cell types, a similar pattern to normoxia was 
observed, with the exception of olaparib. However, cisplatin induced consistently the 
largest effect.  
 
 
3.8.3 Comparisons of Clonogenic Analysis in Normoxia and Hypoxia 
 
Though all comparisons between the two conditions of each drug treatment in each cell 
line were insignificant (p>0.05), various differences were observed. Olaparib treatment 
produced a higher percentage of colonies in the SVG p12 cells under hypoxia, than in 
normoxia (90%6% vs. 83%6%). A similar comparison was also seen with the U87-MG 
cells (103%6% vs. 76%15%). The TMZ treated SVG p12 cells had a lower percentage 
of colonies in hypoxia, compared to normoxia (88%8% vs. 102%29%). Whereas, in 
the U87-MG cells, a higher percentage was observed in hypoxia (73%5% vs. 
60%13%). Cisplatin produced a much lower percentage of colonies in SVG p12 cells in 
hypoxia, compared to normoxia (79%6% vs. 100%25%), but a higher percentage in 
U87-MG cells in hypoxia, than in normoxia (55%8% vs. 50%13%). 
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Figure 3.25: Bar charts showing comparisons of the quantity of colonies visualised 
following drug treatment under hypoxia. The quantity of colonies observed presented as 
a percentage of the respective control following 10-days after drug treatment in hypoxia 
(1% O2). (A) SVG p12, (B) U87-MG. Data represent meanSEM of five consecutive 
independent repeats. Note no significant differences were observed (p>0.05). 
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Chapter 4: 
 
 
Discussion  
 76 
Currently, there are only limited therapeutic options available for GBM and other 
high-grade gliomas due to several reasons, including the presence of the BBB, the 
heterogeneity of the tumours, and their ability to become resistant to drug treatments 
(Karpel-Massler, et al., 2014). Also due to the median overall survival (<15 months) of 
GBM patients, the requirement to develop new treatment strategies has increased 
(Karpel-Massler, et al., 2014). In previous work, evidence has established that PARP1 
is widely expressed in GBM, and that interfering with PARP1 function may be a beneficial 
strategy to overcome drug resistance and also enhance cytotoxicity of existing therapies 
(Karpel-Massler, et al., 2014).  
 
The main aim of this study was to investigate the effect of olaparib, alone and in 
combination with other chemotherapeutics, on a GBM cell line in vitro. While variation 
was observed between assays, evidence has been obtained in this project of the effects 
of olaparib in U87-MG GBM cells, resulting in decreases in cell proliferation, 
accompanied by impairment of cell cycle progression and an increase in apoptosis and 
DNA damage.  
 
 
4.1 Drug Effects on Cell Viability 
 
Initially, this study was designed to examine the effect of olaparib on cell viability in 
SVG p12 and U87-MG cells. As the oxygen levels in the intra-tumoural environment can 
affect the efficacy of drug treatments, the assays were performed under both normoxia 
(21% O2) and hypoxia (1% O2), with the exception of the comet assay. 
 
Olaparib produced decreases in both SVG p12 cell and U87-MG cell viability, 
although its effects were clearly not as potent and rapid as TMZ and cisplatin. With an 
increase in concentration and over a 72-hour time period, olaparib was observed to 
cause a reduction in cell viability at the highest concentration of 0.3 mM in both cell lines 
and in both conditions. This result agrees with findings from a study by Karpel-Massler, 
et al., (2014), who concluded that olaparib alone elicited mild to moderate effects on 
U87-MG cell viability, though only a 10 µM concentration of olaparib for 48-hours was 
used. Rasmussen, et al., (2016) found PARP inhibition by olaparib to be efficient in 
causing cytotoxicity in GBM cells in vitro and in vivo, even when administered alone. 
They used three xenografted GBM cell lines, and a concentration of olaparib based on 
the IC50 values for each cell line (9.0 µM, 11.7 µM, 724.9 nM), and cell viability was 
measured over 7-days (Rasmussen, et al., 2016). Many mechanisms can explain 
olaparib’s cytotoxicity due to PARP1 having a functional role in transcriptional regulation, 
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cell death as well as in DNA repair. Therefore, interfering with PARP1 can lead to 
synthetic lethality in all of these pathways, even when extensive DNA damage is not 
present (Ko & Ren, 2012). A potent effect of olaparib was not observed in this project, 
this may be due to the different cell lines used and that cell viability was only measured 
over 3-days and not longer. 
 
Temozolomide and cisplatin demonstrated their cytotoxic effects by causing a 
decrease in cell viability of both cell lines in a concentration- and time-dependent 
manner, under both normoxia and hypoxia. This result was expected due to these drugs 
being potent chemotherapeutic agents. Castro, et al., (2015) found that TMZ-treated 
U87-MG cells, at a concentration of 25 µM, after 24-hours of treatment showed 80% 
viability. This study measured cell viability over 3-days, and at 72-hours was when the 
largest decrease was observed. Kumar-Thakor, et al., (2017) also found cisplatin (10-7-
10-4M) to induce a concentration- and time-dependent decrease in U87-MG cells’ viability 
under normoxia, over 3-days. These results from previous studies agree with the results 
gained from the current study.  
 
In this project, olaparib had similar efficacy on cell viability in both cell lines under 
both conditions. When compared to TMZ and cisplatin treatment, olaparib had less of an 
effect in both cell lines under both normoxia and hypoxia. TMZ and cisplatin, in this study, 
were observed to induce greater reductions in cell viability 48-hours after treatment. They 
are extremely effective cancer treatments (Lee, 2016; Rocha, et al., 2014), and due to 
the mechanism of action of cisplatin which exerts cytotoxicity by producing DNA lesions, 
and TMZ being an alkylating agent (Fig. 4.1), may be the reason why rapid reductions in 
cell viability were observed 48-hours after drug treatment. This statement agrees with 
findings by Kumar-Thakor, et al., (2017) who concluded that cisplatin might have a 
delayed effect until after 48-hours of treatment. Similarly, Rasmussen, et al., (2016) 
found olaparib can decrease cell viability over 7-days. Therefore, it would be expected 
for TMZ and cisplatin to induce their effects quicker than olaparib, which suggests even 
though olaparib may be a better alternative for normal cells due to the delayed 
cytotoxicity, is not as effective as the current therapies on reducing GBM cell viability. 
 
Based on the results obtained in this project for this assay, scope for future work 
may include the use of different cell lines, such as the xenografted GBM cell lines used 
in the 2016 study by Rasmussen et al. and also to measure cell viability over a longer 
period of time, such as 7-days, instead of only 3-days.  
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Figure 4.1: Diagram showing the mechanisms of action of temozolomide and cisplatin 
in cells, and how they ultimately induce apoptosis of the cells.  
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4.2 Olaparib Decreased Cell Proliferation Over 7 days 
 
As cell viability is determined by many factors or mechanisms, this study 
subsequently decided to examine the effects of olaparib on cell proliferation. Findings 
from this assay indicate a decline over 7-days in CFDA-SE fluorescence in the GBM and 
SVG p12 cell lines under normoxia and hypoxia conditions. A decrease in fluorescence 
corresponds to proliferation of cells over the time period, though variation between the 
cell lines and treatments were present. Olaparib caused a decrease in proliferation over 
the 7-days, especially in the U87-MG cells under normoxia. These results correlate with 
the study by Karpel-Massler, et al., (2014), who obtained findings that olaparib caused 
inhibition of proliferation in U87-MG cells, although this was concentration-dependent. 
 
The results for TMZ and cisplatin do not coincide with what would be presumed to 
be seen. This would be a halt in proliferation in both cell lines. Yu, et al., (2016) 
determined TMZ to have concentration-dependent inhibitory effects on proliferation in 
U87 cells, at a concentration range of 0-3.2 mM for 72-hours. Similarly, Kutwin, et al., 
(2017) found cisplatin to also decrease proliferation in U87 and U118 GBM cell lines 24-
hours after treatment, though at an unknown concentration. In this study, although results 
were not significant, cisplatin definitely inhibited proliferation in U87-MG cells under 
normoxia, and SVG p12 and U87-MG cells under hypoxia.  
 
TMZ and cisplatin under normoxia caused more of a time-dependent decrease in 
CFDA-SE fluorescence in the SVG p12 cells than in the U87-MG cells, implying the SVG 
p12 cells were proliferating more quickly. In contrast, the opposite effect was observed 
in hypoxia. A similar efficacy of olaparib on proliferation was observed in SVG p12 cells 
under both conditions, though a significant effect was seen in the U87-MG cells under 
hypoxia compared to normoxia. This may be due to the involvement of hypoxia-inducible 
factors (HIFs) in hypoxic conditions. Previous studies have found that cancer cell 
proliferation and invasion are linked to HIF expression, and also that they contribute to 
the hypoxic tumoural microenvironment (Yang, et al., 2015). HIF-induced transcription 
regulates many genes which promote proliferation (Monteiro, et al., 2017). Gonzalez-
Flores, et al., (2014) reported that PARP1 regulates HIF-1 activity, but also that PARP1 
interacts with HIF-2α and inhibition of PARP1 affected complex formation and protein 
stability of HIF-2α. The HIF-α subunits are regulated by oxygen availability and under 
hypoxic conditions, hydroxylation is inhibited which causes increased HIF-α stability. 
PARP1 was found to be present at the HIF-2α promoter, therefore PARP1 inhibition 
considerably decreased HIF-2α mRNA and protein levels, as well as HIF-2-dependent 
genes’ transcription. Thus, Gonzalez-Flores, et al., (2014) concluded that inhibition of 
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PARP1 results in multiple regulatory effects on the HIF-2-mediated hypoxic response at 
both the transcriptional and post-transcriptional level. While this is known about the 
crosstalk between HIF and PARP, exactly how this relates to the results from the current 
study would require further investigation. 
 
Based on the proliferation results obtained in this project, scope for future work may 
include to measure proliferation of the cell lines following drug treatment in both a time- 
and concentration-dependent manner. This would allow for proliferation to be measured 
at a range of different concentrations of the drugs, as well as over a period of 7-days.  
 
 
4.3 Olaparib Caused Cell Cycle Arrest 
 
As olaparib was found to inhibit cell proliferation, this study next examined cell cycle 
distribution using propidium iodide staining and flow cytometry. In normoxic conditions, 
olaparib induced the greatest population of GBM and SVG p12 cells to arrest in the G2/M 
phase. This was also the same for the SVG p12 cells in hypoxic conditions. Although the 
greatest population of GBM cells were not present in G2/M in hypoxia, there was a 
definite increase when compared to the control. Studies examining olaparib’s effects on 
cell cycle arrest in either cell line were not found, however another study by Rasmussen, 
et al., (2016) investigated olaparib in three other GBM cell lines under normoxia. They 
found olaparib to induce cell cycle arrest during the G2/M phase in all three of these cell 
lines. Even though they used different GBM cells, this result coincides with the findings 
gained from this project. 
 
Under normoxia, TMZ caused a decrease in the percentage of the population of 
GBM cells in the G0/G1 phase, the percentage of apoptotic cells increased, G2/M 
increased, but S phase was unchanged, when compared to the non-treated control. 
These results partly correlate with a study by Carmo, et al., (2011). Although they used 
the U-118 glioma cell line, they did find similar results with TMZ (Carmo, et al., 2011). 
Other studies have also found TMZ to induce cell cycle arrest during the G2/M phase 
(Filippi-Chiela, et al., 2013; Tiek, et al., 2018). Wang, et al., (2017) found that the 
proportion of GBM cells in the G2/M phase increased in a concentration- and time-
dependent manner following TMZ treatment. They stated that the G2/M arrest by TMZ 
was induced by DNA damage. The use of alkylating agents during chemotherapy 
enhances genotoxic-stress induced DNA damage, and the most vital biological response 
to this is cell death. Activation of cellular mechanisms, including DNA repair and cell 
cycle arrest regulate this biological response immediately following DNA damage. 
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GADD45A, a downstream gene of the tumour-suppressor TP53, has been found to be 
immediately induced by DNA damage by genotoxic drugs, such as TMZ and cisplatin. 
GADD45A is a stress-induced protein that interacts with other cellular molecules involved 
in maintaining genomic stability, regulation of the cell cycle at the G2/M checkpoint, 
apoptosis and DNA repair (Wang, et al., 2017). Thus, it is tempting to suggest that 
GADD45A may be involved in causing the TMZ-treated GBM cells to arrest the cell cycle 
during the G2/M phase.  
 
Cisplatin also caused an increase in the population of U87-MG cells in the apoptotic 
and G2/M phase, and a decrease in the G0/G1 phase under normoxia, though these 
results were not significant when compared to the non-treated control. A 2015 study by 
Jia, et al., observed cisplatin to significantly induce cell cycle arrest during the apoptotic 
phase in U87-MG cells. Kumar-Thakor, et al., (2017) also found cisplatin to cause a 
decrease in the proportion of U87-MG cells in the G0/G1 phase and an increase in the 
G2/M phase, following 48-hours of treatment. Findings from both of these previous 
studies correlate with the results from this current study. Cisplatin induces cytotoxicity 
via DNA intercalation which can cause apoptosis and alterations in the cell cycle (Kumar-
Thakor, et al., 2017). Interestingly, an effect that was replicated in this study where cell 
cycle arrest was observed during the G2/M phase under normoxia.  
 
Under hypoxic conditions, the cell cycle for TMZ-treated cells was G0/G1 dominant, 
and cisplatin was G2/M dominant. Findings from the study by Kumar-Thakor, et al., 
(2017) do not correlate with the results from the present study as they found cisplatin 
treatment to cause a lower proportion of cells to arrest in the G2/M phase under hypoxia 
compared to normoxia. They reported that hypoxic conditions slow the progression of 
the cell cycle, whereas oxygen levels at 1%, also known as moderate hypoxia, induces 
pre-S-phase arrest in cells and cells in other cell cycle phases progress to late G1 phase 
before they arrest. It has been suggested that this transient arrest in the G1 phase is a 
mechanism to protect cells from proceeding into the S phase, where they are more 
susceptible to hypoxia-related DNA damage (Kumar-Thakor, et al., 2017). The G1 phase 
cell cycle checkpoints are activated in response to stress, such as hypoxia, and also 
when the tumour suppressor gene p53 accumulates in response to DNA damage 
(Graeber, et al., 1994). Thus, indicating that under hypoxia the treatments would be 
expected to arrest the cell cycle during the G0/G1 phase, this correlates with current 
findings in this study for TMZ, but not for cisplatin. The present results do indicate though 
that TMZ and cisplatin can inhibit proliferation in the U87-MG cell line. 
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In the SVG p12 cells, TMZ induced a G2/M arrest and this correlates with the results 
for U87-MG cells where a similar increase in the proportion of cells were seen, when 
compared to the control under normoxia. Whereas, cisplatin caused an increase in the  
apoptotic population and potentially a decrease in the G2/M phase, though this does not 
correlate with the U87-MG cells result where a G2/M arrest was observed. Under 
hypoxia, TMZ caused an increase in the proportion of cells in the S phase and cisplatin 
induced the greatest percentage of arrest during the G2/M, similar to the U87-MG cells.  
 
Scope for future work based on these results may be to measure cell cycle arrest 
using different GBM cell lines, such as the U-118 cell line. Previous studies obtained 
results that correlated with the findings from this project, though they examined the 
effects of olaparib and TMZ in other GBM cell lines. Also, the effects of the drug 
treatments on cell cycle arrest could be measured in a concentration-dependent manner.  
 
 
4.4 Olaparib Monotherapy Did Not Induce Apoptosis  
 
Another factor-determining change in cell viability is cell death, in particular 
apoptosis. Using PI and Annexin V staining this study examined any effects of olaparib. 
In U87-MG GBM cells, olaparib did not induce apoptosis in a time-dependent manner 
under either normoxia or hypoxia. Karpel-Massler, et al., (2014) investigated the effects 
of olaparib on apoptosis in the U251 GBM cell line and they found olaparib to induce 
apoptosis after 24-hours of treatment, a finding which coincides with previous results 
from this study where olaparib was observed to have minor cytotoxic effects on the U87-
MG cells.  
 
Under normoxia, TMZ caused an increase in the proportion of live GBM cells over 
the 3-day period, but no change in apoptotic cells. Previous studies have found 
correlating results regarding TMZ-induced apoptosis in U87-MG cells. Knizhnik, et al., 
(2013) concluded that TMZ in U87-MG cells induces apoptosis 120-hours and onwards 
following treatment at a concentration of 35 mM. Wang, et al., (2017) also found the 
effects of TMZ (25 µg/ml) in U87 and U373 cells on apoptosis to be more prominent 4-
days after treatment. Findings have been established that numerous genes involved in 
genome stability, cell survival and DNA repair are up-regulated in response to the 
cytotoxic effects that occur after TMZ treatment. Certain genes, such as GADD45A, have 
been suggested to have anti-apoptotic and protective roles in GBM. Thus, possibly 
suggesting why TMZ treatment takes longer to induce its apoptotic effects, however this 
is yet to be established (Wang, et al., 2017). In hypoxia, TMZ induced a decrease in the 
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percentage of live GBM cells. This suggests the cytotoxic effects of TMZ may be 
enhanced in low oxygen conditions, which would be beneficial due to the intra-tumoural 
environment of GBM being hypoxic (Jawhari, et al., 2016). However, no change was 
observed in the apoptotic population. Resistance to chemotherapy and radiation is 
generally associated with hypoxia, and findings from a 2012 study by Sun, et al., 
concluded that hypoxic tumours have survival benefits, hence indicating TMZ to not 
significantly induce apoptosis in hypoxic conditions. Ahmed, et al., (2018) reported the 
downregulation of HIF-1α increased sensitivity of U87 GBM cells to TMZ. 
 
In this study, the results show that cisplatin caused a significant increase in the 
population of apoptotic U87-MG cells under normoxia; a result that correlates with a 
previous study conducted which investigated cisplatin, at a concentration of 10 µM, over 
72-hours on U87-MG and SVG p12 cell lines (Kumar-Thakor, et al., 2017). Cytotoxic 
effects of cisplatin can cause variations in the DNA structure which interfere with DNA 
replication. Cisplatin uses passive diffusion to enter cells and induces cytotoxicity by 
DNA intercalation, hence initiating apoptosis (Kumar-Thakor, et al., 2017). In this project, 
cisplatin induced significantly greater apoptotic effects in hypoxia on GBM cells; though 
not a result which corresponds to a study by Kumar-Thakor, et al., (2017), whom 
established the efficacy of cisplatin to be reduced in hypoxia. HIFs are known to be the 
primary mediators of hypoxic responses. The HIF factor, HIF-1α has been found to 
stimulate glioma cancer stem cells survival under hypoxic conditions, and HIF-2α is 
believed to be associated to the GBM stem cell phenotype within the hypoxic niche 
(Ahmed, et al., 2018). A decrease in oxygen levels activates transcription of HIF, which 
results in changes in cellular metabolism, and this is caused by transcription of various 
genes including EGFR (epidermal growth factor receptor), VEGFR (vascular endothelial 
growth factor receptor) and GLUT-1 (glucose transporter-1). Hypoxia promotes the 
malignant phenotype of cancerous cells, and an enhanced resistance to chemotherapy 
and radiation is often exhibited (Kumar-Thakor, et al., 2017). In another study, Ahmed, 
et al., (2018) determined that the downregulation of HIF-2α increased sensitivity of U87 
cells to cisplatin, thus, suggesting why previous studies did not observe an increase in 
apoptosis under hypoxia.  
 
The combination treatment of olaparib and TMZ under normoxia produced only a 
slightly higher percentage of apoptotic GBM cells over the 3-days. This may have been 
expected due to the lack of an effect from TMZ alone. The combination of PARPi and 
TMZ has been suggested to enhance the apoptotic rate of a cell population (Dréan, et 
al., 2016). A study by Engert, et al., (2015) observed an increase in apoptosis following 
48-hours of treatment with the combination of olaparib (0.3 µM/L) and TMZ (50 µM/L) 
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using Ewing sarcoma cell lines. A similar decrease in the proportion of live and apoptotic 
cells over the 72-hour time-period was observed under hypoxia for this combination 
treatment. Previous studies have not yet established an explanation for this, as it is still 
an area for research. However, from previous findings in this project, olaparib and TMZ 
alone were observed to have enhanced effects in hypoxic conditions. 
 
Olaparib combined with cisplatin induced significant increases in apoptosis in both 
normoxia and hypoxia. Cisplatin’s mechanism of action is largely based on DNA damage 
and the production of DNA adducts. Previous studies discovered that PARPi did not 
change the quantity of DNA adducts formed by cisplatin, but rather delayed the repair of 
them (Dréan, et al., 2016; Miknyoczki, et al., 2003); agreeing with the suggestion that 
PARPi do not potentiate chemo-resistance, but that the effects observed of combination 
treatment are additional (Dréan, et al., 2016; Murai, et al., 2014). Previous research 
regarding olaparib and cisplatin combined in hypoxia was not found, but from the results 
of this study, this combination treatment induced a greater percentage of apoptosis, also 
implying from what we know of that enhanced cytotoxicity is caused in low oxygen 
conditions. 
 
Some of the results obtained for the SVG p12 cell line were not anticipated. This 
may be due to several reasons, but one study has established a possible cause. 
Henriksen, et al., (2014) determined that SVG p12 cells specifically obtained from the 
American Type Culture Collection contain the infectious BK polyomavirus (BKPyV) of 
strain UT and various defective mutants. Strain UT had been discovered in urine and in 
tumours of different patients beforehand but is also commonly used in research. 
Therefore, it is not clear whether BKPyV was present in the brain tissue which was used 
to produce the cell line or whether it is contamination (Henriksen, et al., 2014). Thus, this 
cell line is not 100% representative of normal glial cells and this may have also affected 
the results for the SVG p12 cells in this study.  
 
Based on the results obtained in this project, future work may include examining the 
effects of apoptosis following drug treatment over a range of time periods rather than just 
3-days. Different GBM cell lines could also be used, as some previous studies have. 
Western blotting could be conducted to identify the different proteins involved in the 
signalling pathways. Previous studies who investigated the effects of apoptosis following 
the combination treatments under hypoxic conditions were not found, therefore this 
would also be scope for future work.  
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4.5 Olaparib, Alone and in Combination, Induced Autophagy 
 
Autophagy is a survival mechanism for cells that precedes apoptosis. Using CYTO-
ID staining solution and flow cytometric analysis, the effects of olaparib were 
investigated. Olaparib produced similar effects on autophagic fluorescence in both 
normoxic and hypoxic conditions. Very limited research investigating olaparib on 
autophagy in U87-MG cells was found in the literature to support these results, 
suggesting this area of research requires attention. However, previous studies 
investigating olaparib in ovarian cancer cells determined that olaparib did induce 
autophagic effects (Sui, et al., 2015), which partly coincides with our findings. However, 
the method used by Sui, et al., (2015) was to inject the cell lines into mice and treated 
them once daily at a dose of 30 mg/kg for 3-weeks, so any disparity may be as a result 
of this. From the other autophagy results, it may also be expected that olaparib would 
induce greater autophagy in hypoxia, though this was not observed. 
 
TMZ treatment in GBM cells caused little change in autophagic fluorescence 
compared to the non-treated control. Previous studies have reported TMZ treatment to 
induce autophagy in GBM cells. Knizhnik, et al., (2013) found that glioma cells underwent 
autophagy in a specific time-dependent manner following 24-144-hours after TMZ (100 
µM) treatment in U87-MG and LN-229 cell lines. However, even though TMZ induces 
autophagy, it provides GBM cells with resistance to the treatment (Jawhari, et al., 2016). 
In the current study, under hypoxia, TMZ caused no change in autophagic fluorescence 
when compared to normoxia. Autophagy is a highly regulated mechanism that can be 
activated in response to certain stimuli, such as conditions of starvation including hypoxia 
(Knizhnik, et al., 2013). Therefore, as hypoxia has been found to induce autophagy 
(Jawhari, et al., 2016) the effects of hypoxia and TMZ treatment combined should have 
caused a greater percentage of fluorescence, than in normoxia, though this was not 
observed in current results. However, this study only tested autophagy induction 
following 24-hours of drug treatment, so this may have been too early to observe any 
effects.  
 
Similar findings were observed for cisplatin where an increase in autophagic 
fluorescence was induced in hypoxic conditions, when compared to the non-treated 
control and also compared to under normoxia. A study by Zhang, et al., (2015) reported 
cisplatin (10 µg/ml) can induce autophagy, and their findings supported the results of the 
present study; though they treated U251 GBM cells for 6, 12, and 24-hours. As a 
cytotoxic agent, cisplatin is hypothesised to cause cell death by DNA damage and 
inhibition of DNA synthesis, however it has been established that cisplatin can also 
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induce cell death through endoplasmic reticulum (ER) stress in vitro and in vivo (Zhang, 
et al., 2015). The ER is the location of regulating protein synthesis, protein folding 
following synthesis and accumulation, stress reaction, and regulating calcium ion levels. 
Changes in the microenvironment of tumour cells, such as hypoxia, or anti-tumour drugs, 
can cause ER stress, including accumulation of unfolded and misfolded proteins in the 
ER and an abnormality in the intracellular calcium ion balance. Eventually, proteins that 
fail to be folded correctly are degraded by the proteasomal and autophagy pathways 
(Zhang, et al., 2015). Hence concluding ER stress, caused by cisplatin, hypoxia or a 
combination of both can induce autophagy. This observation suggests the reason why 
an increased effect was observed in the results of the present study in low oxygen 
conditions, compared to normoxic conditions.  
 
Both of the combination treatments with olaparib produced increases in autophagic 
fluorescence under both normoxia and hypoxia, with significant increases under hypoxia. 
These results correlate closely with those obtained in this study following TMZ and 
cisplatin treatment alone, as they also induced a higher percentage of fluorescence in 
hypoxic conditions. Therefore, these findings suggest when TMZ and cisplatin are 
combined with olaparib, greater effects are exerted on the GBM cells. Previous studies 
have not established results for these combination treatments on autophagy in U87-MG 
cells, however various studies have determined how combined treatments with a PARPi 
enhances cytotoxicity in GBM (Dréan, et al., 2016). Therefore, based on the MOA of 
TMZ and cisplatin, it is logical for olaparib to increase autophagy.  
 
Some of the results for autophagy can be associated with those of the apoptosis 
assay. Previous studies (Knizhnik, et al., 2013) that have investigated TMZ, after 
comparing the time course of apoptosis and autophagy after TMZ treatment, established 
that autophagy precedes apoptosis. These studies demonstrated how a single-type of 
DNA lesion induced by TMZ, O6-methylguanine (O6MeG), produces three different end-
points in glioma cells: autophagy, senescence and apoptosis. The authors found that 72-
hours after treatment autophagy was significantly induced, which reaches a maximum at 
96-hours and then decreases thereafter; cellular senescence was induced 72-hours 
following treatment which steadily increases with time; while apoptosis is the last 
response that becomes significant 120-hours after treatment; this was investigated in 
LN-229 GBM cells (Knizhnik, et al., 2013). Therefore, this may explain why in the current 
results, TMZ alone and in combination with olaparib only induced apoptosis slightly. This 
may also be a reason for olaparib treatment due to its MOA, though this is not fully 
known.  
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Very limited research is present in the literature that investigates olaparib and the 
combination of olaparib with TMZ or cisplatin in GBM cells on autophagy in both normoxic 
and hypoxic conditions, therefore this is scope for future work. In this project, autophagy 
was measured 24-hours after drug treatment, however previous studies that examined 
TMZ found that glioma cells underwent autophagy in a specific time-dependent manner. 
Therefore, autophagy could be measured following 24-144-hours after drug treatment. 
Other studies also used different GBM cell lines to measure the effects of drug treatments 
on autophagy. Therefore, these are possibilities for future work. 
 
 
4.6 Olaparib Induced DNA Damage in U87-MG GBM Cells 
 
The comet assay detects the amount of DNA damage a drug treatment can induce 
following treatment. These results can confirm the data of previous assays including the 
apoptosis assay as the proportion of DNA damage caused can be observed clearly. 
Olaparib was observed to induce DNA damage in the U87-MG GBM cells, which even 
though this does not correlate with the apoptosis results, these findings do confirm 
olaparib alone does cause DNA damage. Previous studies have not investigated the 
effects of olaparib treatment alone on DNA damage in U87-MG cells. However, other 
research was found in the literature to support the effects of olaparib in other cancers. 
Wang, et al., (2016) performed the comet assay and found that olaparib can induce minor 
DNA damage in ovarian cancer cells; though it was 48-hours after drug treatment. Kwon, 
et al., (2016) observed a moderately high level of DNA damage in cisplatin-resistant head 
and neck cancer cells. This was determined 72-hours after olaparib treatment. Thus, the 
time-point used in the current study may have been too early to effectively assess the 
effect of olaparib on DNA damage. 
 
TMZ treatment, when compared to the non-treated control, induced the greatest 
amount of DNA damage in the U87-MG cells. This was expected for TMZ as it is a potent 
chemotherapeutic agent. Castro, et al., (2015) found results that partly correlate with the 
present findings regarding TMZ (25 µM) and that they observed DNA damage in U87 
cells, though only at an intermediate level.  
 
Cisplatin was predicted to induce DNA damage similar to TMZ, as cisplatin is also a 
potent chemotherapeutic drug that induces DNA damage by crosslinking to the purine 
bases on DNA (Dasari & Tchounwou, 2014), however, this was not observed in the 
present study. This finding does not coincide with a study by Kutwin, et al., (2017), who 
determined cisplatin to induce lethal DNA damage in U87 GBM cells. The comet assay 
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is considered sensitive in detecting both SSB and DSBs (Braafladt, et al., 2016). 
However, this assay is commonly used for detecting SSBs as the initial damage 
produced by a treatment (Kawaguchi, et al., 2010). An explanation for cisplatin’s results 
could not be discovered, suggesting that this is an area for further research. However, 
previous findings from this study have shown cisplatin to induce apoptosis and a 
decrease in cell viability, at an identical concentration of 300µM and also after 24-hours 
of treatment. 
 
The DNA damage caused in the SVG p12 cells, when compared to the U87-MG 
cells, was fairly similar. Olaparib, however, induced a higher level of DNA damage in the 
GBM cells than in the SVG p12 cells. Previous studies were not found that have 
investigated DNA damage by olaparib on normal glial cell lines, however Fulton, et al., 
(2018) reported that even though PARP1 is regularly over-expressed in GBM, it is barely 
detectable in normal brain. Thus, this observation suggests olaparib may induce fewer 
adverse effects on normal cells than the current treatments. 
 
Two different analysis methods were used in this study to interpret the results of the 
comet assay. The first method obtained the total intensity of both the head and the tail 
individually by drawing around each segment point-by-point. Whereas, the second 
method only provides an average of the intensity of the entire comet, and this was gained 
by starting at the top of the comet tail and drawing a straight line to the bottom. Also, the 
results from both methods for the H2O2 and TMZ treatments do not correlate. H2O2 was 
used as a positive control so the results obtained from the first method were expected. 
This finding suggests the second method of analysis is less effective at detecting DNA 
damage in the comet assay. Gyori, et al., (2014) performed the comet assay on rat 
muscle cell lines, and conducted analysis using the intensity profile method. This 
correlates closely with the first method employed in the current study. No previous 
studies were found that used the second method of image analysis. This indicates that 
it has not yet been fully established by previous studies which analysis method is more 
effective, therefore further research is required. 
 
Based on the findings obtained in this project for the comet assay, scope for future 
work may include further investigation of the effects of olaparib on DNA damage in GBM 
cells, and also over a longer period of time, as this project only measured DNA damage 
following 24-hours of drug treatment. Further research is also required to examine 
different analysis methods to interpret results to establish which method is more effective 
in detecting DNA damage. 
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4.7 Drug Effects on Colony Formation 
 
The clonogenic assay is based on the ability of a single cell to grow into a colony, 
and it was performed to further investigate the drug treatments on the survival and 
proliferation of the cells under normoxia and hypoxia. Olaparib induced an expected 
minor reduction in colony-formation in the U87-MG cells under normoxia. This finding 
coincides with a study by Irwin, et al., (2014) who also reported that olaparib did induce 
a reduction in the number of surviving colonies in U87 GBM cells. A similar result was 
not obtained under hypoxia, instead no change was observed. This result was not what 
would be expected due to PARP1’s involvement with the HIF factors, and inhibition of 
PARP1 led to multiple regulatory effects on the HIF-2-mediated hypoxic response at both 
the transcriptional and post-transcriptional level (Gonzalez-Flores, et al., 2014). Previous 
studies relating to this finding were not found though; therefore, further research would 
be required. 
 
In normoxia, TMZ and cisplatin induced clear decreases in the number of colonies 
observed in the U87-MG cells, which was expected from these positive control 
treatments. Pasi, et al., (2014) reported TMZ to induce a reduction in clonogenicity, when 
compared to the control, in T98G and U251-MG cells; though in a different GBM cell line, 
these findings correlate with the results of the present study. Cisplatin in U87 cells was 
investigated by Combs, et al., (2012), and they found it to reduce clonogenic survival 
with increasing concentrations. Similar findings for TMZ and cisplatin were also obtained 
in hypoxic conditions. Though previous studies who examined TMZ or cisplatin in GBM 
cell lines were not found, another study by Abyaneh, et al., (2017) investigated cisplatin 
(33.2µM) under hypoxia in MDA-MB-231, a triple negative breast cancer cell line. After 
24-hours of treatment, they found that cells cultured under hypoxia had a significantly 
higher number of colonies than under normoxia. Therefore, even though a decrease in 
colony formation under hypoxia was seen in my results, other studies do not correlate 
with this. All drug treatments were observed to be less effective under hypoxia compared 
to normoxia, which suggests the cells could have been treated for longer prior to counting 
the colonies.  
 
The findings obtained for the SVG p12 cells under normoxia, especially, were not 
what would be expected for TMZ and cisplatin treatments, but instead a decrease should 
have been observed, similar to what was seen with the U87-MG cells. The variation of 
these results was wider than the others, however, the results under hypoxia were not as 
varied. The reasoning behind the unusual SVG p12 results may be due to the high 
temperature in the laboratory when this assay was conducted. A study by Bergs, et al., 
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(2016) investigated the effects of hyperthermia on a human squamous lung carcinoma 
cell line. Hyperthermia is known to be a very potent chemo- and radiosensitiser, that can 
be effective even at mild temperatures. It was determined that temperatures of 42-48ºC 
for 30-120 minutes can induce genotoxic effects (Bergs, et al., 2016). Therefore, if 
temperatures in the laboratory were extremely higher than normal, the effects of the drug 
treatments should have increased. A decrease in colony formation should have also 
been observed for the non-treated control, however this was not seen, especially as for 
this assay the colonies were not counted until 10-days later.  
 
Scope for future work based on the results of this assay include further research on 
the effects of olaparib, TMZ and cisplatin on colony-formation in GBM cells under 
hypoxia. In this project, the colonies were counted after 10-days, however by doing this 
only a single result was obtained. Therefore, the assay could be stopped at different 
timepoints to count the colonies formed, in order to generate a range of results and 
ensure the drug treatments are effective.  
 
 
4.8 Conclusion 
 
Figure 4.2 summarises the main findings of this study. The results from this study 
have demonstrated that olaparib does induce cytotoxic effects on U87-MG GBM cells in 
vitro, and fewer effects were induced on the SVG p12 cells, compared to TMZ and 
cisplatin. Stronger cytotoxicity in the GBM cells was observed when administered in 
combination with other drug treatments, compared to when olaparib was given alone. 
Therefore, combination treatments with olaparib may be a better treatment option for 
GBM. As the dual effects of PARP inhibition by olaparib and the DNA damage by either 
TMZ or cisplatin would be expected to induce enhanced cytotoxicity in GBM tumours in 
vivo to potentially provide an improved prognosis and increase long-term survival of 
patients. 
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Figure 4.2: Diagram showing the mechanism of action of temozolomide and cisplatin, 
and how with the inhibition of PARP1 by olaparib, apoptosis of the cells is ultimately 
induced. 
 
 
4.9 Future Work 
 
In this project, while significant work has been completed, due to the variability in 
the results, certain assays, such as the apoptosis and clonogenic assays, may need 
repeating to verify the results. As Knizhnik, et al., (2013) stated apoptosis is not observed 
until 120-hours and onwards after drug treatment. Therefore, it would be beneficial to 
perform this assay over a longer period of time to ensure the effects of drug treatment 
on apoptosis is observed. For the clonogenic assay, because the results obtained in this 
study were not as expected, it would be required to repeat this assay in order to verify 
the results. 
 
The comet assay could also be performed under hypoxic conditions to determine 
the proportion of DNA damage induced in hypoxia, when compared to normoxia. All other 
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assays in this project were conducted under both conditions for comparisons to be made. 
Also, as the microenvironment of a GBM tumour is extremely hypoxic (Jawhari, et al., 
2016), it would be beneficial to establish the effects of drug treatments under hypoxic 
conditions, as well as normoxic conditions.  
 
The effects of olaparib in the SVG p12 cell line  were unexpected at times during the 
study, which may be because the cells are not 100% representative of normal glial cells 
due to the BKPyV infection. Therefore, this would require further research in order to 
clearly establish to what extent normal cells would be affected. Using primary cells or 
short-term cultures may be beneficial, as a better understanding of how the drug 
treatments induce effects could be established. 
 
Administration of combination drug treatments requires additional investigation to 
determine the effects of olaparib and TMZ or cisplatin in all assays. This would provide 
a wider understanding on whether combination treatments enhance the therapeutic 
effects for GBM.  
 
Triplet combination therapies of PARP inhibition, radiotherapy and TMZ have been 
observed to induce extra synergistic lethality, compared to doublet therapy (Lim & Tan, 
2017), so this is another field for further research.  
 
Further study on the mechanism(s) of action of olaparib as a PARP1 inhibitor is 
required. Studies have stated that olaparib is an inhibitor for both PARP1 and PARP2 
(Rasmussen, et al., 2016), therefore future studies could determine how olaparib exerts 
its effects on GBM cells. An siRNA approach could be used to do this; knocking down 
the expression of PARP1 could establish whether olaparib is inducing its effects through 
that particular enzyme or others. This would be useful as an siRNA is a very selective 
knockdown approach, and no previous studies have conducted this before.  
 
Olaparib has been observed to induce cytotoxicity in BRCA-mutated cancers, 
including ovarian and breast tumours. When either BRCA1 or BRCA2 is defective, HR, 
which is essential for DSBs repair, becomes dysfunctional. If HR cannot repair the 
damage, alternative repair mechanisms are activated. Therefore, if a patient is deficient 
in BRCA and olaparib inhibits PARP, the unrepaired DNA SSBs and DSBs will ultimately 
result in cell death (Lorusso, et al., 2018). Currently, an association between BRCA 
germline mutation and GBM malignancy has not been established. However, 
Boukerroucha, et al., (2015) investigated two patients with a BRCA1 germline mutation 
treated for breast cancer, who developed GBM a few years later. They concluded that 
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the loss of heterozygosity did not occur as the tumour-suppressor protein expression is 
maintained in GBM at the protein and mRNA levels, implying that a BRCA mutation is 
not associated with GBM development. Another study by Elmariah, et al., (2006) 
reported a BRCA1-mutated patient who developed GBM, though they did not investigate 
this further. Studies on the risk of brain tumour development in BRCA carriers were 
conducted in 1994 and 2002 (Boukerroucha, et al., 2015); since then techniques have 
immensely evolved. Therefore, whether there may be a hidden link between BRCA 
mutation and GBM development is an extensive area for further research and whether 
olaparib treatment could potentially be more beneficial in these patients, as well as in 
GBM overall. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 94 
 
5 References 
 
Abyaneh, H.S., Gupta, N., Radziwon-Balicka, A., Jurasz, P., Seubert, J., Lai, R. and 
Lavasanifar, A. (2017). STAT3 but Not HIF-1α Is Important in Mediating Hypoxia-Induced 
Chemoresistance in MDA-MB-231, a Triple Negative Breast Cancer Cell Line. Cancers, 
9(10): 137-153. 
 
Ahmed, E.M., Bandopadhyay, G., Coyle, B. and Grabowska, A. (2018). A HIF-
independent, CD133-mediated mechanism of cisplatin resistance in glioblastoma cells. 
Cellular Oncology (Dordrecht), 41(3): 319-328. 
 
Allen, M., Bjerke, M., Edlund, H., Nelander, S. and Westermark, B. (2016). Origin of 
the U87MG glioma cell line: Good news and bad news. Science Translational Medicine, 
8(354): 1-4. 
 
Annovazzi, L., Mellai, M. and Schiffer, D. (2017). Chemotherapeutic Drugs: DNA 
Damage and Repair in Glioblastoma. Cancers, 9(6): 57-73. 
 
AstraZeneca. (2018). Lynparza tablets receive EU approval for the treatment of 
platinum-sensitive relapsed ovarian cancer. [Online] Available at: 
https://www.astrazeneca.com/media-centre/press-releases/2018/lynparza-tablets-
receive-eu-approval-for-the-treatment-of-platinum-sensitive-relapsed-ovarian-
cancer08052018.html [Accessed 10 July 2018]. 
 
Ben-Hur, E., Chen, C.C. and Elkind, M.M. (1985). Inhibitors of Poly(adenosine 
Diphosphoribose) Synthetase, Examination of Metabolic Perturbations, and 
Enhancement of Radiation Response in Chinese Hamster Cells. American Association 
for Cancer Research, 45(5): 2123-2127. 
 
Bergs, J.W., Oei, A.L., Ten-Cate, R., Rodermond, H.M., Stalpers, L.J., Barendsen, 
G.W. and Franken, N.A. (2016). Dynamics of chromosomal aberrations, induction of 
apoptosis, BRCA2 degradation and sensitization to radiation by hyperthermia. 
International Journal of Molecular Medicine, 38(1): 243-250. 
 
Boukerroucha, M., Josse, C., Segers, K., El-Guendi, S., Frères, P., Jerusalem, G. 
and Bours, V. (2015). BRCA1 germline mutation and glioblastoma development: report 
of cases. BMC Cancer, 15(1): 181-187. 
 95 
 
Braafladt, S., Reipa, V. and Atha, D.H. (2016). The Comet Assay: Automated 
Imaging Methods for Improved Analysis and Reproducibility. Scientific Reports, 6(1): 
32162-32171. 
 
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A. (2018). 
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality 
worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68(6): 
394-424. 
 
Brown, G.L., Eckley, M. and Wargo, K.A. (2010). A Review of Glioblastoma 
Multiforme. Pharmacist, 35(5): 3-10. 
 
Brown, J.S., Kaye, S.B. and Yap, T.A. (2016). PARP inhibitors: the race is on. British 
Journal of Cancer, 114(7): 713-715. 
 
Cancer Research UK. (2018). Cancer Statistics for the UK. [Online] Available at: 
https://www.cancerresearchuk.org/health-professional/cancer-statistics-for-the-
uk#heading-Three [Accessed 9 December 2018]. 
 
Carmo, A., Carvalheiro, H., Crespo, I., Nunes, I. and Lopes, M.C. (2011). Effect of 
temozolomide on the U-118 glioma cell line. Oncology Letters, 2(6): 1165-1170. 
 
Castro, G.N., Cayado-Gutiérrez, N., Zoppino, F.C.M., Fanelli, M.A., Cuello-Carrión, 
F.D., Sottile, M., Nadin, S.B. and Ciocca, D.R. (2015). Effects of temozolomide (TMZ) on 
the expression and interaction of heat shock proteins (HSPs) and DNA repair proteins in 
human malignant glioma cells. Cell Stress & Chaperones, 20(2): 253–265. 
 
Chalmers, A. (2017). A trial looking at olaparib with temozolomide for glioblastoma 
that has come back (OPARATIC). [Online] Available at: 
http://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-at-
olaparib-with-temozolomide-glioblastoma-has-come-back#undefined [Accessed 20 
September 2017]. 
 
Chalmers, A., Jackson, A., Swaisland, H., Watts, C., Halford, S., Hargrave, D. and 
McCormick, A. (2016). DDIS-19. Olaparib Penetrates Tumour Margins As Well As 
Contrast Enhancing Regions Of Glioblastoma At Therapeutic Levels: Interim Results Of 
The Oparatic Trial NCT01390571. Neuro-Oncology, 18(6): (an abstract). 
 96 
 
Chen, A. (2011). PARP inhibitors: its role in treatment of cancer. Chinese Journal of 
Cancer, 30(7): 463-471. 
 
Cohen, A., Holmen, S. and Colman, H. (2013). IDH1 and IDH2 Mutations in Gliomas. 
Current Neurology and Neuroscience Reports, 13(5): 345-351. 
 
Coluccia, D., Figueiredo, C.A., Wu, M.Y., Riemenschneider, A.N., Diaz, R., Luck, A., 
Smith, C., Das, S., Ackerley, C., O’Reilly, M., Hynynen, K. and Rutka, J.T. (2018). 
Enhancing glioblastoma treatment using cisplatin-gold-nanoparticle conjugates and 
targeted delivery with magnetic resonance-guided focused ultrasound. Nanomedicine: 
Nanotechnology, Biology and Medicine, 14(4): 1137-1148. 
 
Combs, S.E., Zipp, L., Rieken, S., Habermehl, D., Brons, S., Winter, M., Haberer, 
T., Debus, J. and Weber, K.J. (2012). In vitro evaluation of photon and carbon ion 
radiotherapy in combination with chemotherapy in glioblastoma cells. Radiation 
Oncology, 7(1): 9-14. 
 
Dasari, S. and Tchounwou, P.B. (2014). Cisplatin in cancer therapy: molecular 
mechanisms of action. European Journal of Pharmacology, 740(1): 364-378. 
 
Davis, M.E. (2016). Glioblastoma: Overview of Disease and Treatment. Clinical 
Journal of Oncology Nursing, 20(5): 2-8. 
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